document incorporate reference specify portion registrant proxy statement file commission pursuant regulation connection registrant annual meeting stockholder hold incorporate reference iii report base closing price share june exclude share registrant common stock hold executive officer director stockholder ownership exceed registrant common stock outstanding june exclusion share construe indicate person possess power direct indirect direct cause direction management policy registrant person control common control registranttable content gilead sciences inc annual report table content item business item risk factor item b unresolved staff comment item property item legal proceeding item submission matter vote security holder ii item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure item b information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service iv item exhibit financial statement schedule signature right trademark copyright trade name business include follow gilead gilead sciences truvada viread emtriva hepsera ambisome vistide letairis volibris atripla register trademark belong bristol myers squibb gilead sciences llc macugen register trademark belong osi pharmaceuticals inc sustiva register trademark bristol myers squibb pharma company tamiflu register trademark belong hoffmannla roche inc flolan register trademark smithkline beecham corporation report include trademark service mark trade name companiestable content annual report include section entitle management discussion analysis financial condition result operation contain forwardlooke statement future event future result subject safe harbor create security act amend securities act securities exchange act amended exchange act word expect anticipate target goal project hope intend plan believe seek estimate continue variation word similar expression intend identify forwardlooke statement addition statement statement historical fact forward look statement include statement overall trend operate cost trend liquidity capital need statement expectation belief future plan strategy anticipate event trend similar expression base forwardlooke statement current expectation future event statement guarantee future performance involve risk uncertainty assumption difficult predict actual result differ materially suggest forwardlooke statement reason include identify risk factor beginning give risk uncertainty caution place undue reliance forwardlooke statement forward look statement include report date hereof require federal security law rule regulation securities exchange commission sec undertake specifically decline obligation update statement publicly announce result revision forwardlooke statement distribution report result new information future event change assumption table content item business overview gilead sciences inc gilead incorporate delaware june biopharmaceutical company discover develop commercialize innovative therapeutic area unmet medical need mission advance care patient suffer life threaten disease worldwide headquarter foster city california operations north america europe australia date focus effort bring novel therapeutic treatment life threaten disease market continue seek add exist portfolio product internal discovery clinical development program active product acquisition inlicense strategy product truvada emtricitabine tenofovir disoproxil fumarate oral formulation dose day combination therapy treat human immunodeficiency virus hiv infection adult fix dose combination antihiv medication viread tenofovir disoproxil fumarate emtriva emtricitabine atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oral formulation dose day treatment hiv infection adult atripla daily single tablet regimen hiv intend stand therapy combination antiretroviral fix dose combination antihiv medication viread emtriva bristol myerssquibb company nonnucleoside reverse transcriptase inhibitor sustiva efavirenz viread oral formulation nucleotide analogue reverse transcriptase inhibitor dose day combination therapy treat hiv infection adult receive marketing approval viread treatment chronic hepatitis b united states european union country include canada turkey emtriva oral formulation nucleoside analogue reverse transcriptase inhibitor dose day combination therapy treat hiv infection adult united states europe emtriva approve combination therapy treat hiv infection child hepsera adefovir dipivoxil oral formulation nucleotide analogue polymerase inhibitor dose day treat chronic hepatitis b license right commercialize hepsera treatment hepatitis b asia latin america certain territories glaxosmithkline inc gsk ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treat invasive fungal infection cause fungal specie corporate partner astellas pharma inc astellas promote sell ambisome united states canada promote sell ambisome europe australia new zealand letairis ambrisentan endothelin receptor antagonist era indicate treatment pulmonary arterial hypertension pah group patients class ii iii symptom improve exercise capacity delay clinical worsen letairis available special restrict distribution program call letairis education access program leap prescriber pharmacy register leap prescribe sell distribute letairis sublicense gsk right ambrisentan market gsk volibris certain hypertensive condition territory outside united states vistide cidofovir injection antiviral medication treatment cytomegalovirus retinitis patient aid sell vistide united states wholesale channel country outside united states table content flolan epoprostenol sodium inject medication longterm intravenous treatment primary pulmonary hypertension pulmonary hypertension associated scleroderma spectrum disease new york heart association class iii class iv patient respond adequately conventional therapy exclusive right market promote distribute flolan sterile diluent flolan united states april flolan distribute united states specialty pharmacy follow table list aggregate product sale major product thousand total total total product product product sale sale sale antiviral product truvada atripla viread hepsera emtriva total antiviral product ambisome letairis total product sale item note consolidated financial statement include annual report total revenue geographic area royalty product tamiflu oseltamivir phosphate oral antiviral available capsule form treatment prevention influenza b tamiflu approve treatment influenza child adult country include united states japan european union approve prevention influenza child adults united states japan european union develop tamiflu f hoffmannla roche ltd hoffmannla roche inc roche roche exclusive right manufacture sell tamiflu worldwide subject obligation pay royalty base percentage net sale tamiflu worldwide macugen pegaptanib sodium injection intravitreal injection antiangiogenic oligonucleotide treatment neovascular agerelate macular degeneration macugen develop osi pharmaceuticals inc osi technology license promote united states osi osi hold exclusive right manufacture sell macugen united states pfizer inc pfizer hold exclusive right manufacture sell macugen rest world receive royalty osi base sale macugen worldwide commercialization distribution international commercial sale operation marketing subsidiary australia austria belgium canada denmark finland france germany greece ireland italy netherlands new zealand norway portugal spain sweden switzerland turkey united kingdom united states product market commercial team andor conjunction party distributor corporate partner commercial team promote product direct field contact physician table content hospital clinic healthcare provider generally grant party distributor exclusive right promote product territory specify period time agreement distributor provide collaborative effort distributor gilead obtain maintain regulatory approval product specify territory united states commercial team promote truvada viread emtriva hepsera letairis flolan promote atripla united states joint venture partner bristol myerssquibb company bm currently distribute truvada atripla viread emtriva hepsera vistide united states exclusively wholesale channel product sale large wholesaler cardinal health inc mckesson corp amerisourcebergen corp account total revenue year end december combine basis wholesaler account approximately product sale united states approximately total revenue corporate partner astella promote sell distribute ambisome united states product letairis flolan distribute exclusively specialty pharmacy specialty pharmacy specialize dispense medication complex chronic condition require high level patient education ongoing counseling territory outside united states sell distribute truvada viread emtriva hepsera ambisome asia australia europe latin america middle east new zealand commercial team party distributor promote atripla jointly bms majority country europe responsible selling distribute product country limited number central eastern european country bm party distributor sole promote sell distribute company small group noneuropean union eastern central european country atripla promote bms directly party distributor agreement merck co inc merck plan promote distribute atripla country latin america asiapacific merck exist party distributor partner rely corporate partner japan tobacco inc promote sell truvada viread emtriva japan corporate partner astella promotes sell distribute ambisome canada dainippon sumitomo pharma co ltd responsible promotion distribution ambisome japan access develop world gilead access program establish certain gilead hiv product available substantially reduce price country develop world develop system tiere pricing reflect economic status gross national incomegniper capita hiv prevalence approach allow price therapy base country ability pay example high prevalence exist certain country country relatively high gni country move low price tier accommodate high burden disease support clinical study donation product help define good treatment strategy develop world country example november enter collaborative agreement medical research council mrc united kingdom boehringer ingelheim gmbh gsk connection clinical study conduct mrc antiretroviral hiv therapy africa trial call dart development antiretroviral therapy study aim study clinical versus laboratory monitoring practice structure treatment interruption continuous antiretroviral therapy adult hiv infection subsaharan africa provide viread cost dart study work closely world health organization nongovernmental organization provide ambisome treatment leishmaniasis parasitic disease preferential price resource limited setting support numerous clinical study investigate role ambisome treat visceral cutaneous leishmaniasis develop country collaboration organization drug neglect disease initiative mdecin san frontire table content enter number collaboration relate access product develop world include pharmachem technologies grand bahama ltd pharmachem technologies establish facility bahama manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread active pharmaceutical ingredient truvada atripla resource limited country cooperative effort pharmachem technology grand bahama port authority aspen pharmacare holdings ltd aspen october enter nonexclusive manufacturing distribution agreement aspen provide manufacture distribution viread truvada treatment hiv infection certain develop world country include gilead access program november amend agreement aspen amend agreement aspen retain right manufacture distribute viread truvada treatment hiv infection certain develop world country gilead access program aspen right purchase viread truvada britestock form distribution country right manufacture viread truvada active pharmaceutical ingredient purchase aspen supplier approve aspen grant right manufacture distribute generic version emtricitabine tenofovir disoproxil fumarate include version tenofovir disoproxil fumarate combination emtricitabine treatment hiv infection aspen require pay royalty net sale viread truvada royaltie net sale generic version tenofovir disoproxil fumarate include version tenofovir disoproxil fumarate combination emtricitabine manufacture distribute aspen generic license enter nonexclusive license agreement indian generic manufacturer grant right produce distribute generic version tenofovir disoproxil fumarate treatment hiv infection low income country world include india low income country gilead access program agreement require generic manufacturer meet certain national international regulatory standard include technology transfer enable expeditious production large volume high quality generic version tenofovir disoproxil fumarate addition agreement allow manufacture commercial quantity active pharmaceutical ingredient finish product merck august enter agreement affiliate merck pursuant provide atripla substantially reduce price hiv infect patient develop country africa caribbean latin america southeast asia agreement manufacture atripla efavirenz supply merck merck handle distribution product country cover agreement international partnership microbicide ipm conrad december enter agreement grant right ipm conrad cooperate agency agency international development usaid committed improve reproductive health expand contraceptive choice woman man develop manufacture prove efficacious arrange distribution resource limited country tenofovir microbicide prevent hiv infection competition product development program target number area include viral fungal respiratory cardiovascular disease commercially available product treatment disease company institution make substantial investment develop additional product treat disease product compete available product base primarily efficacy safety table content tolerability acceptance doctor ease patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing hiv product hiv landscape competitive complex treatment trend continue evolve grow number antihiv drug currently sell advanced stage clinical development approximately brand hiv drug available united states product primarily compete fix dose combination product nucleotidenucleoside reverse transcriptase inhibitor nrti class include combivir lamivudinezidovudine epzicomkivexa abacavirlamivudine trizivir abacavirlamivudinezidovudine sell gsk hiv product compete directly product nrti class sell bms hiv product compete broadly hiv product abbott laboratories inc boehringer ingelheim gmbh merck pfizer roche tibotec therapeutic division ortho biotech products lp subsidiary johnson johnson bmss videx ec didanosine ddi generic hiv product united states gsk retrovir zidovudine face generic competition united states result launch generic zidovudine gsk zerit stavudine face generic competition united states result launch generic stavudine date little impact generic didanosine zidovudine stavudine price hiv product price decrease hiv product result long term ambisome ambisome face strong competition current expect competitor competition current expect competitor erode revenue receive sale ambisome ambisome face competition vfend voriconazole develop pfizer caspofungin product develop merck market cancidas united states caspofungin ambisome compete lipidbase amphotericin b product include abelcet amphotericin b lipid complex injection sell enzon pharmaceuticals inc united states canada japan zeneus pharma ltd europe amphotec amphotericin b cholesteryl sulfate complex injection sell river pharmaceutical llc worldwide anfogen amphotericin b liposomal sell genpharma sa argentina bms numerous generic manufacturer sell conventional amphotericin b compete ambisome aware lipid formulation claim similarity ambisome available outside united state include possible entry formulation greece formulation reduce market demand ambisome furthermore manufacture lipid formulation amphotericin b complex formulation find unsafe sale ambisome negatively impact association hbv product hepatitis b virus hbv product hepsera viread face significant competition exist expect therapy treat patient chronic hepatitis b hbv product face competition baraclude entecavir oral nucleoside analogue develop bms launch united states tyzekasebivo telbivudine oral nucleoside analogue develop novartis pharmaceutical corporation novartis sale united states european union china table content hbv product compete epivirhbvzeffix lamivudine develop gsk collaboration shire pharmaceuticals group plc sell major country north south america europe asia hepsera viread treatment hepatitis b compete establish immunomodulatory therapy include introna interferon alfab sell schere plough corporation major country north south america europe asia pegasys pegylate interferon alfaa injectable drug similar introna sell roche treatment chronic hepatitis b letairis letairis compete directly tracleer bosentan sell actelion pharmaceutical inc indirectly pah product united therapeutics corporation pfizer vistide vistide compete number drug treat cytomegalovirus retinitis include cytovene iv cytovene ganciclovir sell intravenous oral formulation roche ocular implant bausch lomb incorporate valcyte valganciclovir market roche foscavir foscarnet intravenous drug sell astrazeneca plc vitravene fomivirsen drug inject directly eye sell cibavision flolan flolan compete primarily remodulin treprostinil form prostacyclin administer continuous subcutaneous infusion continuous intravenous infusion sell united therapeutics corporation united states flolan compete ventavis iloprost inhale form prostacyclin sell affiliate actelion ltd united states addition patent covering flolan expire generic pharmaceutical company launch generic version flolan united states tamiflu tamiflu compete relenza zanamivir antiinfluenza drug sell gsk relenza neuraminidase inhibitor deliver orallyinhale dry powder generic competitor include amantadine rimantadine oral tablet inhibit replication influenza virus biocryst pharmaceuticals inc develop injectable formulation peramivir influenza neuraminidase inhibitor treatment influenza currently phase clinical trial macugen macugen compete primarily visudyne verteporfin injection sell novartis connection photodynamic therapy lucentis ranibizumab sell genentech inc number company pursue development technology competitive research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently pharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program collaborative relationship business strategy establish collaboration company university medical research institution assist clinical development andor commercialization certain product product candidate provide support research program evaluate opportunity acquire product right product technology complementary business company university medical research institution information certain relationship include ongoing financial accounting impact business find item note consolidated financial statement page include annual report table content commercial collaboration currently number collaboration corporate partner govern manufacture sale distribution andor marketing product territory worldwide follow commercial collaboration significant financial statement perspective significant ongoing collaboration activity exist bristolmyer squibb company bms december enter collaboration bms develop commercialize single tablet regimen truvada bmss sustiva united states combination approve use united states july sell atripla bms structure collaboration joint venture form limited liability company call bristolmyers squibb gilead sciences llc term collaboration bms grant royalty free sublicense joint venture use respective company own technology return grant license joint venture use intellectual property result collaboration economic interest joint venture hold bms include share revenue outofpocket expense base portion net selling price atripla attributable truvada emtricitabine tenofovir disoproxil fumarate sustiva efavirenz respectively net selling price truvada change time relative net selling price sustiva bmss respective economic interest joint venture vary annually bms share marketing sale effort party provide equivalent sale force effort level agree annually bm daily operation joint venture govern primary joint committee form bms responsible accounting financial reporting tax reporting product distribution joint venture september bms amend joint venture collaboration agreement allow joint venture sell atripla canada agreement continue terminate mutual agreement party addition party terminate party participation collaboration day launch generic version party single agent product double agent product nonterminate party right continue sell atripla shortterm obligation pay royalty terminate party december enter collaboration bms set forth term condition bms commercialize atripla european union norway iceland switzerland liechtenstein bm party distributor act sell party country responsible thing receive process customer order warehouse product collect sale handle return manufacture atripla coordinate primarily responsible distribution logistic general party share revenue outofpocket expense proportion net selling price truvada respect efavirenz respect bms agreement terminate expiration expire patent afford market exclusivity atripla component european country cover agreement prior time party terminate agreement reason termination effective december nonterminate party right continue sell atripla obligate pay terminate party certain royalty year period follow effective date termination event nonterminate party decide sell atripla effective date termination date atripla withdraw country date party assume distribution atripla whichever early f hoffmannla roche ltd hoffmannla roche inc roche september enter development license agreement roche develop commercialize therapy treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codevelope roche original agreement roche exclusive right obligation manufacture sell tamiflu worldwide subject obligation pay percentage net sale roche generate tamiflu sale agreement receive upfront payment million entitle receive additional milestone payment million achievement certain development table content regulatory objective receive milestone payment october roche cash payment million relate reimbursement certain research preclinical development expense obligation prosecute maintain certain patent agreement november enter amendment supplement original agreement roche amendment eliminate cost good adjustment royalty calculation retroactive calendar year future calculation amendment provide formation joint manufacturing committee review roche manufacturing capacity tamiflu global plan manufacture tamiflu commercial committee evaluate commercial plan strategy tamiflu united states joint supervisory committee evaluate roche overall commercial plan tamiflu global basis committee consist representative roche amendment option provide specialized sale force supplement roche marketing effort tamiflu exercise date agreement roche obligation pay royalty terminate countrybycountry basis patent provide exclusivity tamiflu country expire roche terminate agreement reason case right tamiflu revert party terminate agreement response material breach party glaxosmithkline inc gsk march exclusively sublicense gsk right ambrisentan active pharmaceutical ingredient letairis market volibris territory outside united states certain hypertensive condition territory outside united states license agreement receive upfront payment million subject achievement specific milestone eligible receive total additional milestone payment million december receive million potential milestone payment addition receive royalty base net sale volibris gsk territory gsk option negotiate exclusive sublicense additional therapeutic use volibris gsk territory term license agreement agreement continue conduct bear expense clinical development activity believe required obtain maintain regulatory approval letairis volibris united states canada european economic area party conduct additional development activity territory expense party agree jointly develop ambrisentan new indication license field party pay share external cost associate joint development agreement gsk obligation pay royalty terminate countrybycountry basis early date generic equivalent sell country achieve certain percentage total prescription product plus generic equivalent fifteenth anniversary commercial launch country gsk terminate agreement reason termination event right product revert party terminate agreement response material breach party research collaboration currently number collaboration corporate partner govern research development certain compound drug candidate follow research collaboration significant financial statement perspective significant ongoing collaboration activity exist abbott laboratories inc abbott june enter exclusive worldwide license agreement abbott develop commercialize darusentan condition oncology initial license payment total million term agreement abbott right negotiation participate copromotion product right negotiation exclusive development commercialization partner japan addition obligate future milestone payment million achievement certain regulatory approval pay royalty base net sale table content successfully commercialize drug indication obligate use commercially reasonable effort develop commercialize product certain country commercialize darusentan certain country abbott market product affect market pay royalty sale darusentan currently study phase clinical trial treatment patient resistant hypertension december million milestone payment obligation pay royalty terminate country bycountry basis patent provide exclusivity product country expire terminate agreement certain circumstance include determine product reasonable likelihood commercial success case right responsibility product revert abbott party terminate agreement response material breach party japan tobacco inc japan tobacco march enter licensing agreement japan tobacco japan tobacco grant exclusive right develop commercialize elvitegravir novel hiv integrase inhibitor country world exclude japan japan tobacco retain right agreement responsible seek regulatory approval territory require use diligent effort commercialize product treatment hiv bear cost expense associate commercialization effort term agreement pay upfront license fee million obligate total potential milestone payment million achievement certain clinical regulatory commercial objective additionally obligate pay royalty base net sale territory market product december total milestone payment million agreement obligation pay royalty japan tobacco terminate productbyproduct basis patent provide exclusivity product expire later tenth anniversary commercial launch product terminate agreement reason case license grant japan tobacco terminate party terminate agreement response material breach party research development addition enter collaboration company university medical research institution seek add exist portfolio product internal discovery clinical development program active inlicense product acquisition strategy acquisitions myogen inc corus pharma inc acquire navitas asset llcs asset relate cicletanine business evaluate potential treatment pah research scientist foster city san dimas california durham north carolina seattle washington boulder westminster colorado engage discovery development new molecule technology hope lead new medicine novel formulation exist drug product development effort cover wide range medical condition include hivaid liver disease cardiovascular disease respiratory disease summary key product correspond current stage development additional information development pipeline visit website wwwgileadcom table content product candidate description marketing application pende aztreonam inhalation solution treatment new drug application nda aztreonam inhalation solution treatment cystic fibrosis cystic fibrosis cf submit food drug administration fda november september receive complete response letter fda inform fda approve nda aztreonam inhalation solution treatment cf current form request conduct additional phase clinical study november file request formal dispute resolution fda february response appeal fda notify reiterate position need conduct clinical study aztreonam inhalation solution resubmit nda submit marketing authorization application european union receive notice acceptance priority review health canada approval canada await response respective regulatory body phase ambrisentan ambrisentan oral era evaluate treatment idiopathic pulmonary fibrosis ipf darusentan darusentan oral era investigate addon therapy patient resistant hypertension elvitegravir elvitegravir oral integrase inhibitor evaluate combination therapy hiv treatment experience patient prepare phase ambrisentan ambrisentan go evaluate treatment chronic allograft injury kidney transplant recipient pulmonary hypertension patient ipf phase gs gs oral nonnucleoside polymerase inhibitor evaluate combination therapy peginterferon alfa ribavirin treatmentnave hepatitis c virus hcv infected patient genotype gs gs inhaled coformulation fosfomycin tobramycin evaluation bacterial infection associate cf gs gs oral caspase inhibitor evaluation treatment inflammatory fibrotic condition include hcv nonalcoholic steatohepatitis aztreonam inhalation solution aztreonam inhalation solution evaluate bronchiectasis cicletanine cicletanine oral agent development pah prepare phase gs gs pharmacoenhancer development boost agent certain hiv medicine elvitegravir gs truvada fourinone fix dose regiman combine elvitegravir gs tenofovir disoproxil fumarate emtricitabine evaluation treatment hivaid treatmentnave patient table content product candidate description phase gs gs nucleotide analogue evaluation topical ointment patient external genital perianal wart cause human papilloma virus infection gs gs nucleotide analogue evaluation patient nonhodgkin lymphoma chronic lymphocytic leukemia gs gs oral epithelial sodium channel blocker design increase airway hydration patient pulmonary disease total research development expense million compare million million patent proprietary right patent proprietary right important business properly design enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology rely trade secret internal knowhow technological innovation agreement party develop maintain protect competitive position ability competitive depend success strategy number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent follow table show actual estimate expiration date united states europe primary patent patent issue pende application cover compound market product patent european patent product expiration expiration vistide hepsera letairis ambisome tamiflu macugen viread emtriva truvada atripla supplementary protection certificate protection obtain certain european country confer auxiliary form patent exclusivity base european patent expiration date viread component truvada patent cover active pharmaceutical ingredient truvada atripla viread emtriva hepsera letairis vistide hold party acquire exclusive right patent agreement table content party patent cover active ingredient ambisome instead hold patent liposomal formulation compound protect formulation trade secret addition patent filing china certain asian country cover form adefovir dipivoxil active ingredient hepsera application pende country asia include china relate specific form formulation hepsera asia major market therapy hepatitis b infection indication hepsera develop patent cover flolan market exclusivity protection expired result generic pharmaceutical company launch generic version flolan united states obtain patent certain product year obtain marketing approval product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension example extension patent product grant united states number european country compensate delay obtain marketing approval similar patent term extension available product develop certain obtain important infringe patent proprietary right violate agreement grant proprietary right infringe patent violate agreement prevent develop selling product process cover patent agreement require obtain license party allow use technology certain require obtain license party technology obtain reasonable cost able obtain require license alternative technology unable develop commercialize product business adversely affect example aware body patent relate operation leap restrict distribution program design support letairis addition actelion market tracleer apply patent claim method use era treatment ipf issue patent interfere effort commercialize era ambrisentan ipf patent application confidential period time patent issue know competitor file patent application technology cover pende application invent technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete patent competitor file patent application cover technology participate interference proceeding litigation determine right patent litigation interference proceeding expensive ultimately successful result operation adversely affect event patent relate pharmaceutical biopharmaceutical biotechnology product compound process cover exist compound product process likely file future provide complete adequate protection future litigation examination proceeding enforcement validity exist patent future patent invalidate patent substantially reduce protection example public patent foundation file request reexamination united states patent trademark office pto challenge patent relate tenofovir disoproxil fumarate active ingredient truvada atripla viread pto grant request issue nonfinal rejection patent step common proceeding initiate reexamination process pto confirm patentability patent successful respond pto office action instance similar organization challenge patent foreign jurisdiction example april brazilian health ministry cite pende patent reexamination proceeding ground rejection request table content brazilian patent authority issue decision supportive patent application tenofovir disoproxil fumarate brazil august examiner brazilian patent authority issue final rejection fumarate salt patent application patent application tenofovir disoproxil fumarate file brazil file appeal patent authority respond question raise rejection predict outcome proceeding tenofovir disoproxil fumarate patent application unable successfully appeal decision patent authority court brazilian patent authority reject tenofovir disoproxil fumarate patent application tenofovir disoproxil fumarate patent application reject brazilian patent authority brazilian government likely purchase generic tenofovir disoproxil fumarate significantly reduce sale hiv product brazil pende patent application patent application file collaborative partner result issuance patent result patent provide adequate protection result able prevent party develop compound product closely relate developed develop addition certain country africa asia include china permit enforcement patent party manufacturer able sell generic version product country approval process product fda grant exclusivity period manufacturer application approval generic version product grant generic manufacturer wait challenge patent protect product grant exclusivity year prior end exclusivity period time time receive notice manufacturer indicate intend import chemical intermediate possibly use make product possible generic manufacturer consider attempt seek fda approval similar identical drug abbreviate new drug application anda application form typically manufacturer seek approval generic drug patent subject challenge need spend significant resource defend challenge able defend patent successfully example november receive notice teva pharmaceutical submit anda fda request permission manufacture market generic version truvada notice teva allege patent associate emtricitabine own emory university license exclusively invalid unenforceable andor infringe tevas manufacture use sale generic version truvada december file lawsuit district court new york teva infringement emtricitabine patent predict ultimate outcome action spend significant resource defend patent unsuccessful lawsuit original claim patent narrow invalidated patent protection truvada united states shorten expire instead rely unpatented trade secret improvement unpatente internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor research development agreement invention jointly own corporate partner case exclusive property party certain circumstance difficult determine own particular invention dispute arise invention table content august pto adopt new rule schedule effective november october gsk successfully obtain preliminary injunction implementation rule april court rule support gsk challenge rule obtain permanent injunction implementation rule restrict number claim permit patent application number continue patent application file follow court rule pto file notice appeal federal court appeal pto successfully appeal court decision rule implement limit ability obtain broad patent coverage product product candidate allow competitor market product similar obtain patent coverage closely relate product manufacture raw material manufacturing strategy contract party manufacture majority solid dose product rely corporate partner manufacture certain product additionally manufacture facility san dimas california edmonton alberta canada dublin cork ireland manufacture certain product clinical commercial use contract party manufacture certain product clinical commercial purpose include truvada atripla viread emtriva hepsera vistide use multiple party contract manufacturer manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread active pharmaceutical ingredient truvada atripla emtricitabine active pharmaceutical ingredient emtriva active pharmaceutical ingredient truvada atripla adefovir dipivoxil active pharmaceutical ingredient hepsera rely party contract manufacturers tablet capsulate product example use multiple party contract manufacturers tablet truvada atripla viread emtriva hepsera emtriva capsulation complete party contract manufacturer rely single party supplier tablet letairis manufacture agreement corporate partner roche party responsible manufacturing tamiflu agreement roche joint manufacturing committee compose representative roche opportunity review roche exist manufacturing capacity tamiflu global plan manufacture tamiflu gsk affiliate party manufacture flolan distribution united states term distribution supply agreement gsk san dimas facility manufacture fill package product manufacture ambisome exclusively facility depend single supplier high quality cholesterol manufacture ambisome fill finish macugen exclusively facility san dimas manufacturing agreement osi pfizer osi currently provide pegaptanib sodium active pharmaceutical ingredient macugen fill package drug product truvada atripla viread emtriva hepsera finish form facility san dimas fda recently approve facility san dimas manufacture aztreonam inhalation solution subject fda approval product delivery device edmonton alberta facility carry process research scaleup clinical development candidate manufacture active pharmaceutical ingredient investigational product conduct chemical development activity improve exist commercial manufacturing process addition utilize site manufacture emtricitabine manufacture active pharmaceutical ingredient letairis exclusively edmonton site supplier qualify active pharmaceutical ingredient letairis fill package drug product truvada atripla viread emtriva hepsera finish form facility near dublin ireland perform quality control testing final labeling packaging table content ambisome distribution product european union facility utilize cork ireland facility primarily solid dose tablet manufacturing certain antiviral product product packaging activity manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation party manufacturer corporate partner subject fda current good manufacturing practice extensive regulation govern manufacturing process stability testing record keep quality standard similar regulation effect country manufacture operation subject routine inspection regulatory agency additionally party manufacturer corporate partner independent entity subject unique operational financial risk control party manufacturer corporate partner fail perform require impair ability deliver product timely basis receive royalty cause delay clinical trial application regulatory approval extent risk materialize affect performance obligation financial result adversely affect believe technology use manufacture product proprietary product manufacture party contract manufacturer disclose necessary aspect technology enable manufacture product agreement party manufacturer intend restrict manufacturer reveal technology certain party manufacturer comply restriction addition party manufacturer develop technology relate work perform need manufacture product require enter additional agreement party manufacturer want use technology allow manufacturer use technology party manufacturer refuse allow use technology demand term use technology acceptable need access certain supply product manufacture product delivery material supplier interrupt reason unable purchase sufficient quantity raw material manufacture product unable ship certain product commercial supply supply product candidate development clinical trial addition product material utilize operation facility example manufacture ambisome fill finish macugen exclusively facilities san dimas california event natural disaster include earthquake equipment failure difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome macugen meet market need product candidate aztreonam inhalation solution pende fda approval dependent different singlesource supplier aztreonam active pharmaceutical ingredient aztreonam inhalation solution manufacture single supplier single site second administer lung patient device single supplier single site fda recently approve facility san dimas manufacture aztreonam inhalation solution subject fda approval product delivery device san dimas facility manufacturing site authorize manufacture aztreonam inhalation solution pursue fda approval party manufacturer fourth diluent aztreonam inhalation solution manufacture single manufacturer single site problem single supplier depend negatively impact development commercialization effort future product continue consider develop additional manufacturing capability establish additional party supplier manufacture sufficient quantity product candidate undertake clinical trial manufacture sufficient quantity product approve commercial sale unable develop manufacturing capability internally contract large scale manufacturing party acceptable term future product ability conduct large scale clinical trial meet customer demand commercial product adversely affect table content seasonal operation backlog worldwide product sale reflect significant degree seasonality royalty revenue represent total revenue tamiflu royalty comprise significant portion affect seasonality royalty revenue recognize roche sale tamiflu impact severity associate flu season product delivery response avian influenza pandemic threat operate market characterize short lead time absence significant backlog believe backlog information material business government regulation operation activity subject extensive regulation numerous government authority united states countries united states drug subject rigorous fda regulation federal food drug cosmetic act federal state statute regulation govern testing manufacture safety efficacy labeling storage record keeping approval advertising promotion product result regulation product development product approval process expensive time consume fda approve drug sell united states general process approval follow preclinical testing test drug candidate human study drug laboratory experiment animal generate datum support drug candidate potential benefit safety submit datum fda investigational new drug ind application seek approval test compound human clinical trial fda accept ind application study drug candidate human clinical trial determine drug candidate safe effective clinical trial involve separate phase overlap year expensive phase subject considerable regulation follow phase drug candidate give small number healthy human control subject patient suffer indicate disease test safety dose tolerance pharmacokinetic metabolism distribution excretion phase drug candidate give limited patient population determine effect drug candidate treat disease good dose drug candidate possible effect safety risk drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous phase clinical trial phase drug candidate appear effective safe phase clinical trial phase clinical trial commence confirm result phase clinical trial conduct long term involve significantly large population conduct numerous site different geographic region carefully design provide reliable conclusive datum safety benefit drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous extensive phase clinical trial table content fda approval process believe datum phase clinical trial adequate level safety efficacy submit appropriate filing usually form nda supplemental nda fda seek approval sell drug candidate particular use fda hold public hear independent advisory committee expert advisor ask additional question make recommendation drug candidate committee make recommendation fda binding generally follow fda fda agree compound meet require level safety efficacy particular use allow sell drug candidate united states use unusual fda reject application believe drug candidate safe efficacious believe datum submit reliable conclusive point process development drug candidate stop number reason include safety concern lack treatment benefit certain clinical trial currently conduct conduct future complete successfully specified time period choose fda require delay suspend clinical trial time appear patient expose unacceptable health risk drug candidate appear sufficient treatment benefit fda require phase nonregistrational study explore scientific question characterize safety efficacy commercial use drug fda require provide additional data information improve manufacturing process procedure facility require extensive surveillance monitor safety benefit product candidate determine file contain adequate evidence safety benefit drug addition fda approve drug limit use drug fda withdraw approval believe comply regulatory standard problem uncover occur approval addition obtain fda approval drug obtain fda approval manufacturing facility drug sell include company manufacture drug facility subject periodic inspection fda fda approve foreign establishment manufacture product sell united states facility subject periodic regulatory inspection manufacturing facility locate california include san dimas facility license state california compliance local regulatory requirement manufacture facility locate canada include edmonton alberta facility facility locate near dublin cork ireland obtain local license permit compliance local regulatory requirement drug treat life threaten disease condition adequately address exist drug development program design address unmet medical need designate fast track candidate fda eligible accelerate priority review drug treatment hiv designate use president emergency plan aid relief qualify expedite priority review viread truvada atripla receive accelerate approval priority review drug receive accelerated approval monitor post marketing clinical trial order confirm safety benefit drug subject federal state local regulation workplace safety protection environment use hazardous material chemical viruse radioactive compound research development activity eliminate risk accidental contamination injury material misuse accident involve material lead significant litigation fine penalty drug subject extensive regulation outside united states european union centralize approval procedure authorize marketing product country european union table content include major country europe centralize approval procedure approval country european union obtain approval country european union simplified application process mutual recognition procedure decentralize procedure rely principle mutual recognition receive regulatory approval european registration procedure separate pricing reimbursement approval require country price reimbursement successful commercialization product depend availability governmental party payor reimbursement cost product relate treatment government health administration authority private health insurer organization generally provide reimbursement united states european union significant potentially significant market product product candidate government authority party payor increasingly attempt limit regulate price medical product service particularly new innovative product therapy result low average selling price example significant portion sale majority product subject significant discount list price rebate obligation addition increase emphasis manage healthcare united states country regional pricing reimbursement control european union additional pressure product pricing reimbursement usage adversely affect product revenue profitability pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement policy price general legislative regulatory change government prescription drug procurement reimbursement program occur relatively frequently united states foreign jurisdiction significant change federal medicare system recent year united states impact pricing product medicare prescription drug improvement modernization act medicare beneficiary able elect coverage prescription drug medicare prescription drug program begin january benefit patient transition medicaid medicare long term impact medicare business clear impact depend specific decision level coverage provide therapeutic category product include term coverage provide extent preference give select product category party payor provide medicare coverage attempt negotiate price concession pharmaceutical manufacturer addition discussion take place federal level pass legislation allow require federal government directly negotiate price concession pharmaceutical manufacturer set minimum requirement medicare pricing increase pressure low prescription drug price limit drug access medicare enrollee medicare patient pay coinsurance influence product recommend physician select patient result operation materially adversely affect reimbursement change emerge medicare prescription drug coverage legislation addition federal medicare proposal state medicaid drug payment change lower payment product extent private insurer manage care program follow medicaid coverage payment development adverse effect magnify private insurer adopt low payment schedule additionally additional statutory regulatory change include potential change medicare health care reform federal state level adversely affect payment drug demand product time state enact health care reform legislation federal government individual state government continue consider health care reform policy legislation pricing reimbursement environment product change future challenge reason new policy new presidential administration new health care legislation pass congress ryan white program large federal program design provide care support service people live hiv united states provide fund hiv product state aid drug table content assistance program adap patient uninsure underinsured federal funding appropriate congress year provide city state provider organization addition federal funding state locality provide additional funding ryan white services program reauthorize september extended congress change program change decrease funding available hiv product example appropriation ryan white hold previous year people access drug adap likely face pressure provide great discount drug purchase program addition fall state revenue budget cut result reduction state local funding ryan white lead increase demand patient assistance program offer hiv product free charge eligible patient europe success commercialize product product candidate develop depend largely obtain maintain government reimbursement european country patient unlikely use prescription drug reimburse government addition negotiate price governmental authority delay commercialization month example launch atripla france remain reimbursement discussion french government authority reimbursement policy adversely affect ability sell product profitable basis international market government control price prescription pharmaceutical include implementation reference pricing price cut rebate retrospective taxis profit control expect price prescription pharmaceutical decline life product volume increase recent year country european union increase require discount product expect continue country attempt manage health care expenditure especially light global economic downturn new drug come market face significant price decrease product european country believe continue foreseeable future government struggle escalate health care spending result pricing practice difficult maintain historic level profitability achieve expect rate growth government agency issue regulation guideline directly applicable product addition time time professional society practice management group private healthscience foundation organization publish guideline recommendation direct certain health care patient community recommendation guideline relate matter product usage dosage route administration use related compete therapy consequently result increase decrease usage product health care fraud abuse law subject federal state law pertain health care fraud abuse include antikickback law false claim law antikickback law illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business include purchase prescription particular drug breadth statutory provision increase attention give law enforcement authority possible certain practice challenge antikickback similar law false claim law prohibit knowingly willingly present cause present payment party payor include medicare medicaid claim reimburse drug service false fraudulent claim item service provide claim claim medically unnecessary item service sale marketing activity subject scrutiny law violation fraud abuse law punishable criminal andor civil sanction include fine civil monetary penalty possibility exclusion federal health care program include medicare medicaid government allege convict violate law material adverse effect result operation table content november receive subpoena united states attorney office san francisco request document market medical education program truvada viread emtriva comply attorney subpoena continue cooperate relate governmental inquiry compulsory license number develop country government official interested group suggest pharmaceutical company drug hiv infection available low cost alternatively government develop country require grant compulsory license allow competitor manufacture sell version product reduce product sale example past certain office government brazil express concern affordability hiv product declare consider issue compulsory license permit manufacture patent product hiv infection include viread result discussion brazilian government reach agreement brazilian health ministry reduce price viread brazil approximately addition concern cost availability tamiflu relate potential avian flu pandemic generate international discussion compulsory licensing tamiflu patent example canadian government allow canadian manufacturer manufacture export active ingredient tamiflu eligible develop develop country canada access medicine regime furthermore roche issue voluntary license permit party manufacturing tamiflu example roche grant sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drug limited india certain develop country compulsory license issue permit generic manufacturing override tamiflu patent roche issue additional voluntary license permit party manufacturing tamiflu development reduce royalty receive roche sale tamiflu certain country permit enforcement patent manufacturer able sell generic version product country compulsory license sale generic version product significantly reduce sale adversely affect result operation particularly generic version product import territory exist commercial sale employee january approximately fulltime employee believe good relation employee environment seek comply applicable statutory administrative requirement concern environmental quality continue expenditure environmental compliance protection expenditure compliance environmental law expect material effect capital expenditure result operation competitive position information subject information requirement exchange act file periodic report proxy statement information sec report proxy statement information obtain visit public reference room sec f street ne washington dc call sec sec send electronic message sec publicinfosecgov send fax sec addition sec maintain website wwwsecgov contain report proxy information statement information issuer file electronically table content mail address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors section website sec filings financial information section available follow filing soon reasonably practicable electronically file furnished sec annual report quarterly report form q current report form k amendment report file furnish pursuant section exchange act filing available free charge request item risk factor evaluate business carefully consider follow risk addition information annual report manifestation follow risk materially adversely affect business result operation financial condition note factor investor permit private security litigation reform act possible predict identify factor consider follow risk complete statement potential risk uncertainty face substantial portion revenue derive sale hiv product unable maintain continue increase sale hiv product result operation adversely affect currently dependent sale product treatment hiv especially truvada atripla support exist operation hiv product contain tenofovir disoproxil fumarate andor emtricitabine belong nucleoside class antiviral therapeutic treatment paradigm hiv change cause nucleosidebased therapeutic fall favor unable continue increase hiv product sale result operation likely suffer likely need scale operation include spend research development rd effort hiv product sale year end december billion total revenue sales truvada atripla account respectively total hiv product sale able sustain growth rate sale hiv product reason state risk factor section particular follow reason hiv product long period time patient combination product additional study conduct new issue respect safety resistance interaction drug arise cause provide additional warning contraindication label narrow approve indication halt sale product reduce revenue hiv product mature private insurer government reimburser reduce reimburse patient product increase pressure reduce price large market hiv product consist patient take hiv drug successful encourage physician change patient regimen include hiv product sale hiv product limit generic hiv product introduce major market ability maintain pricing market share affect table content inability accurately estimate demand product sale fluctuation result inventory level hold wholesaler pharmacie non retail customer difficult accurately forecast sale cause earning fluctuate adversely affect financial result stock price year end december approximately product sale united states wholesaler cardinal health inc mckesson corp amerisourcebergen corp wholesaler enter inventory management agreement estimate determine end user demand completely effective match inventory level actual end user demand result change inventory level hold wholesaler cause operating result fluctuate unexpectedly sale wholesaler match end user demand addition inventory hold retail pharmacy nonwholesale location inventory management agreement control buy pattern adverse change economic condition factor cause retail pharmacy reduce inventory product reduce order wholesaler consequently wholesalers order end user demand change example fourth quarter strong prescription demand truvada atripla fully reflect revenue fourth quarter believe quarter inventory draw retail distribution channel inventory distribution channel fluctuate quarter quarter continue mismatch prescription demand product revenue addition nonretail sector united states include government institution include state aids drug assistance program adap correctional facility large health maintenance organization tend consistent term buy pattern cause quarter quarter fluctuation necessarily mirror purchasing pattern see retail sector example quarter observe large nonretail purchase small number state adap purchase centrally significant warehousing capacity believe purchase drive grant cycle federal adap fund current patient demand temper order associate product sale revenue earning second quarter organization deplete increase inventory level establish quarter expect continue experience fluctuation purchase pattern nonretail customer result fluctuation product sale revenue earning future estimate future demand product consider shelf life inventory regularly review realizability inventory actual demand estimate demand require record inventory writedown adverse impact result operation stock price fail commercialize new product expand indication exist product prospect future revenue adversely affect introduce new product market increase sale exist product able increase maintain total revenue continue expand rd effort example december committee medicinal product human use european medicine agency emea grant marketing authorization atripla european union treatment hiv infection adult virologic suppression hiv rna level copiesml current combination antiretroviral therapy month patient experience virological failure prior antiretroviral therapy know harbored virus strain mutation confer significant resistance component contain atripla restriction atriplas use european union prevent promote atripla use patient currently achieve reduction viral load use antiretroviral therapy include newly diagnose patient seek expand indication atripla european union emea require perform additional clinical trial unable complete unable expand indication atripla include broad population patient impact future sale atripla table content european union unknown limited market include united states restriction addition sale atripla increase expense product sale component product overall total revenue gross margin increase atripla sale increase marketing authorization application submit aztreonam inhalation solution treatment cystic fibrosis cf united states delay receive complete response letter fda inform fda approve application current form request conduct additional phase clinical study november file request dispute resolution fda determine analyse exist datum lead approval need conduct additional study february response appeal fda notify reiterate position need conduct clinical study aztreonam inhalation solution resubmit new drug application nda exist datum ongoing additional clinical trial commence satisfy fda concern support fda approval aztreonam inhalation solution cause considerable expense lead delay cause abandon development product risk health authority country marketing authorization application pende undertake similar additional review compound risk describe significant portion product sale occur outside united states currency fluctuation cause earning fluctuate adversely affect stock price significant percentage product sale denominate foreign currency primarily euro face exposure adverse movement foreign currency exchange rate dollar strengthen foreign currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative value sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business net foreign currency exchange impact revenue pretax earning include revenue expense generate outside united states favorable million million respectively compare recently dollar appreciate major european currency favorable impact product sale result previously relatively weak dollar decrease use foreign currency forward option contract hedge percentage forecast international sale primarily denominate euro hedge certain monetary asset liability denominate foreign currency reduce eliminate exposure currency fluctuation date transaction record date cash collect pay predict future fluctuation foreign currency exchange rate dollar dollar continue appreciate certain currency hedge program sufficiently offset effect appreciation result operation adversely affect stock price decline face significant competition face significant competition large pharmaceutical biotechnology company substantially great resource addition competitor product operate field compete long hiv product compete primarily product glaxosmithkline inc gsk market fix dose combination product compete truvada atripla hepsera viread treatment chronic hepatitis b compete primarily product produce gsk bristolmyer squibb company bms novartis pharmaceutical corporation novartis united states european union china ambisome compete primarily product produce merck co inc merck pfizer inc pfizer addition aware lipid formulation claim similarity ambisome available outside united state include possible entry formulation greece formulation reduce market demand table content ambisome furthermore manufacture lipid formulation amphotericin b complex formulation find unsafe sale ambisome negatively impact association letairis compete directly actelion pharmaceutical inc actelion indirectly pah product united therapeutics corporation pfizer tamiflu compete product sell gsk generic competitor aztreonam inhalation solution treatment cf approve marketing compete product market novartis addition number company pursue development technology competitive research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently pharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program significant safety issue arise market product product candidate future sale reduce adversely affect result operation datum support marketing approval product form basis safety warning product label obtain control clinical trial limit duration case postapproval use product long period time patient underlie health problem take numerous medicine expect continue find new issue safety resistance drug interaction issue require provide additional warning contraindication label narrow approve indication reduce market acceptance product product letairis approve fda june member class compound call endothelin receptor antagonist pose specific risk include risk liver injury birth defect risk letairis available letairis education access program leap restrict distribution program intend help physician patient learn risk associate product assure appropriate use product product additional patient discover new risk associate letairis result change distribution program additional restriction use letairis decrease demand product example launch letairis case edema certain patient take letairis report information recently add product label negatively impact demand product safety resistance drug interaction issue arise market product include letairis sale product limit halt regulatory authority result operation adversely affect operation depend compliance complex fda comparable international regulation failure obtain broad approval timely basis maintain compliance delay halt commercialization product product develop approve marketing sale regulatory authority approve subject extensive regulation fda comparable regulatory agency country continue clinical trial truvada atripla viread hepsera emtriva ambisome letairis currently approve additional use anticipate file marketing approval additional country additional indication product year product fail receive marketing approval timely basis september receive complete response letter fda inform fda approve nda aztreonam inhalation solution treatment cf current form request conduct additional phase clinical study november file request dispute resolution table content fda determine analyse exist datum lead approval need conduct additional study february response appeal fda notify reiterate position need conduct clinical study aztreonam inhalation solution resubmit nda exist datum ongoing clinical trial additional clinical trial commence satisfy fda concern support fda approval aztreonam inhalation solution cause considerable expense lead delay cause abandon development product risk health authority country marketing authorization application pende undertake similar additional review compound risk describe addition market product manufacture sell product subject extensive regulation review discovery previously unknown problem market product problem manufacture promotional activity result restriction product include withdrawal product market fail comply applicable regulatory requirement subject penalty include fine suspension regulatory approval product recall seizure product criminal prosecution september president bush sign law food drug administration amendment act significantly expand fdas authority include thing require sponsor market product conduct postapproval clinical study assess know risk signal risk identify unexpected risk mandate labeling change product point product lifecycle base new safety information require sponsor implement risk evaluation mitigation strategy product include medication guide patient package insert communication plan healthcare provider element fda deem necessary assure safe use drug include impose certain restriction distribution use product failure comply requirement impose sponsor fda result significant civil monetary penalty result anticipate timeline clinical trial uncertain support continue development product pipeline adversely affect prospect future revenue growth require demonstrate safety efficacy product develop intend use extensive preclinical study clinical trial result preclinical early clinical study accurately predict result later largescale clinical trial successfully complete largescale clinical trial result marketable product product candidate fails achieve primary endpoint clinical trial safety issue arise result clinical trial inadequate support regulatory approval product candidate commercialization product candidate delay halt face challenge clinical trial protocol design clinical trial product candidate pipeline delay terminate prospect future revenue growth adversely impact example face numerous risk uncertaintie product candidate include elvitegravir novel hiv integrase inhibitor darusentan treatment resistant hypertension ambrisentan treatment idiopathic pulmonary fibrosis ipf currently phase clinical trial prevent completion development product candidate risk include ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial perform additional trial risk fail obtain fda regulatory body approval result product candidate successfully commercialize strategic decision discontinue development product candidate example believe commercialization difficult relative opportunity pipeline program table content pipeline complete timely basis prospect future revenue growth adversely impact addition clinical trial involve commercial product raise new safety issue exist product turn decrease revenue harm business reliance party contract research organization conduct clinical trial unable directly control timing conduct expense quality clinical trial extensively outsource clinical trial activity usually perform small portion startup activity inhouse rely independent party contract research organization cro control perform clinical study include document preparation site identification screen preparation prestudy visit training program management bioanalytical analysis dispute disruption relationship cro clinical trial delay regulatory submission rely quality validity clinical work perform party cro cro process methodology result determine invalid inadequate clinical data result relate regulatory approval adversely impact depend relationship company sale marketing performance revenue failure maintain relationship poor performance company dispute company negatively impact business rely number significant collaborative relationship major pharmaceutical company sale marketing performance certain territory include collaboration bms atripla united states europe canada roche tamiflu gsk ambrisentan territory outside united states country rely international distributor sale truvada viread hepsera emtriva ambisome relationship involve clinical development product partner reliance collaborative relationship pose number risk include inability control resource corporate partner devote program product dispute arise respect ownership right technology develop corporate partner disagreement corporate partner cause delay termination research development commercialization product candidate result litigation arbitration contract corporate partner fail provide significant protection fail effectively enforce partner fails perform corporate partner considerable discretion elect pursue development additional product pursue alternative technology product collaboration competitor corporate partner marketing right choose pursue compete technology devote few resource marketing product product development distributor corporate partner unable pay particularly light current economic condition give risk great deal uncertainty success current future collaborative effort effort fail product development commercialization new product delay revenue product decline april licensing agreement gsk give gsk right control clinical regulatory development commercialization hepsera territories asia africa latin america include major market hepsera china japan taiwan south korea success hepsera table content territory depend entirely effort gsk regard gsk promote epivirhbvzeffix product compete hepsera consequently gsk marketing strategy hepsera influence promotion epivirhbvzeffix receive royalty gsk equal percentage gsk net sale hepsera net sale gsk epivirhbvzeffix gsk fail devote sufficient resource succeed develop commercialize hepsera territory potential revenue sale hepsera territory substantially reduce addition letairis distribute party specialty pharmacy pharmacie specialize dispense medication complex chronic condition require high level patient education ongoing counseling use specialty pharmacy require significant coordination sale marketing medical affair regulatory affair legal finance organization involve risk include limited risk specialty pharmacy provide accurate timely information inventory patient data safety complaint effectively sell support letairis devote resource necessary sell letairis volume time frame expect able satisfy financial obligation cease operation rely party administer leap restrict distribution program design support letairis party provide information education prescriber patient risk letairis confirm insurance coverage investigate alternative source reimbursement assistance ensure fulfillment risk management requirement mandate letairis fda coordinates control dispense patient party specialty pharmacy failure party specialty pharmacy distribute letairis perform expect result regulatory action fda decrease letairis sale harm business dependent supplier inhalation device deliver aztreonam inhalation solution regulatory approval obtain distribute device specialty pharmacy distribution channel control key aspect relate device example supplier encounter issue regulatory agency relate device unable supply sufficient quantity device time commercial launch follow launch device subject separate reimbursement approval process event supplier unable obtain reimbursement approval receive approval lowerthanexpecte price sale aztreonam inhalation solution adversely affect addition able obtain adequate supply inhalation device previously describe issue limit delay commercial launch aztreonam inhalation solution adversely affect financial result exist product subject reimbursement government agency party pharmaceutical pricing reimbursement pressure reduce profitability successful commercialization product depend availability governmental party payor reimbursement cost product relate treatment government health administration authority private health insurer organization generally provide reimbursement united states european union significant potentially significant market product product candidate government authority party payor increasingly attempt limit regulate price medical product service particularly new innovative product therapy result low average selling price example significant portion sale majority product subject significant discount list price rebate obligation addition table content increase emphasis manage healthcare united states country regional pricing reimbursement control european union additional pressure product pricing reimbursement usage adversely affect product revenue profitability pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement policy price general europe success commercialize product product candidate develop depend largely obtain maintain government reimbursement european country patient unlikely use prescription drug reimburse government addition negotiate price governmental authority delay commercialization month example launch atripla france remain reimbursement discussion french government authority reimbursement policy adversely affect ability sell product profitable basis international market government control price prescription pharmaceutical include implementation reference pricing price cut rebate retrospective taxis profit control expect price prescription pharmaceutical decline life product volume increase recent year country european union increase discount require product expect continue country attempt manage health care expenditure especially light global economic downturn new drug come market face significant price decrease product european country believe continue foreseeable future government struggle escalate health care spending result pricing practice difficult maintain historic level profitability achieve expect rate growth result operation adversely affect current future health care reform legislative regulatory change government prescription drug procurement reimbursement program occur relatively frequently united states foreign jurisdiction significant change federal medicare system recent year united states impact pricing product medicare prescription drug improvement modernization act medicare beneficiary able elect coverage prescription drug medicare prescription drug program begin january benefit patient transition medicaid medicare long term impact medicare business clear impact depend specific decision level coverage provide therapeutic category product include term coverage provide extent preference give select product category party payor provide medicare coverage attempt negotiate price concession pharmaceutical manufacturer addition discussion take place federal level pass legislation allow require federal government directly negotiate price concession pharmaceutical manufacturer set minimum requirement medicare pricing increase pressure low prescription drug price limit drug access medicare enrollee medicare patient pay coinsurance influence product recommend physician select patient result operation materially adversely affect reimbursement change emerge medicare prescription drug coverage legislation addition federal medicare proposal state medicaid drug payment change lower payment product extent private insurer manage care program follow medicaid coverage payment development adverse effect magnify private insurer adopt low payment schedule additionally additional statutory regulatory change include potential change medicare health care reform federal state level adversely affect payment drug demand product time state enact health care reform legislation federal government individual state government continue consider health care reform policy legislation pricing reimbursement environment product change future challenge reason new policy new presidential administration new health care legislation pass congress table content ryan white program large federal program design provide care support service people live hiv united states provide fund hiv product state aids drug assistance program adap patient uninsure underinsured federal funding appropriate congress year provide city state provider organization addition federal funding state locality provide additional funding ryan white services program reauthorize september extended congress change program change decrease funding available hiv product example appropriation ryan white hold previous year people access drug adap likely face pressure provide great discount drug purchase program addition fall state revenue budget cut result reduction state local funding ryan white lead increase demand patient assistance program offer hiv product free charge eligible patient expense associate clinical trial cause earning fluctuate adversely affect stock price clinical trial require regulatory approval product clinical trial require conduct approval expensive difficult accurately predict control timing expense quarter quarter uneven unexpected spending program cause operating result fluctuate quarter quarter stock price decline success depend significant degree ability protect patent intellectual property right domestically internationally able obtain effective patent protect technology use competitor patent company require stop pay use require technology patent proprietary right important business success depend significant degree ability obtain patent license patent right preserve trade secret operate infringe proprietary right properly design enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent patent application confidential period time patent issue result know competitor file patent application technology cover pende application invent technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete patent addition competitor file patent application cover technology participate interference proceeding litigation determine right patent litigation interference proceeding expensive ultimately successful result operation adversely affect event table content time time certain individual entity challenge patent example public patent foundation file request reexamination united states patent trademark office pto challenge patent relate tenofovir disoproxil fumarate active ingredient truvada atripla viread pto grant request issue nonfinal rejection patent step common proceeding initiate reexamination process pto confirm patentability patent successful respond pto office action instance similar organization challenge patent foreign jurisdiction example april brazilian health ministry cite pende patent reexamination proceeding ground rejection request brazilian patent authority issue decision supportive patent application tenofovir disoproxil fumarate brazil august examiner brazilian patent authority issue final rejection fumarate salt patent application patent application tenofovir disoproxil fumarate file brazil file appeal patent authority respond question raise rejection predict outcome proceeding tenofovir disoproxil fumarate patent application unable successfully appeal decision patent authority court brazilian patent authority reject tenofovir df patent application tenofovir disoproxil fumarate patent application reject brazilian patent authority brazilian government likely purchase generic tenofovir disoproxil fumarate significantly reduce sale hiv product brazil patent cover active ingredient ambisome addition patent filing china certain asian country cover form adefovir dipivoxil active ingredient hepsera asia major market therapy hepatitis b infection indication hepsera develop flolan patent market exclusivity protection expired result generic pharmaceutical company launch generic version flolan united states obtain patent certain product year marketing approval obtain product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension approval process product fda grant exclusivity period manufacturer application approval generic version product grant generic manufacturer wait challenge patent protect product grant exclusivity year prior end exclusivity period time time receive notice manufacturer indicate intend import chemical intermediate possibly use make product possible generic manufacturer consider attempt seek fda approval similar identical drug abbreviate new drug application anda application form typically manufacturer seek approval generic drug patent subject challenge need spend significant resource defend challenge able defend patent successfully example november receive notice teva pharmaceutical submit anda fda request permission manufacture market generic version truvada notice teva allege patent associate emtricitabine own emory university license exclusively invalid unenforceable andor infringe tevas manufacture use sale generic version truvada december file lawsuit district court new york teva infringement emtricitabine patent predict ultimate outcome action spend significant resource defend patent unsuccessful lawsuit original claim patent narrow invalidated patent protection truvada united states shorten expire instead august pto adopt new rule schedule effective november october gsk successfully obtain preliminary injunction implementation rule april court rule support gsk challenge rule obtain permanent table content injunction implementation rule restrict number claim permit patent application number continue patent application file follow court rule pto file notice appeal federal court appeal pto successfully appeal court decision rule implement limit ability obtain broad patent coverage product product candidate allow competitor market product similar obtain patent coverage closely relate product success depend large ability operate infringe patent proprietary right party infringe patent prevent commercialize product require obtain license party able obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product example aware body patent relate operation leap restrict distribution program design support letairis addition actelion market tracleer apply patent claim method use endothelin receptor antagonist era treatment ipf issue patent interfere effort commercialize era ambrisentan ipf furthermore use significant proprietary technology rely unpatented trade secret proprietary knowhow protect certain aspect production technology trade secret know independently discover competitor manufacturing problem delay product shipment regulatory approval adversely affect result operation depend party perform manufacturing activity effectively timely basis majority solid dose product addition roche party responsible manufacturing tamiflu manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation party manufacturer corporate partner subject fda current good manufacturing practice gmp extensive regulation govern manufacturing process stability testing record keep quality standard similar regulation effect country manufacture operation subject routine inspection regulatory agency additionally party manufacturer corporate partner independent entity subject unique operational financial risk control party manufacturer corporate partner fail perform require impair ability deliver product timely basis receive royalty cause delay clinical trial application regulatory approval extent risk materialize affect performance obligation financial result adversely affect ability successfully manufacture commercialize aztreonam inhalation solution approve depend ability manufacture multi product facility aztreonam monobactam gramnegative antibiotic currently plan manufacture party multiproduct manufacturing facility historically fda permit manufacture monobactam multiproduct manufacturing facility assurance fda continue allow practice currently singleproduct facility dedicated manufacture aztreonam inhalation solution engage contract manufacturer singleproduct facility aztreonam inhalation solution fda prohibit manufacture monobactam antibiotic like aztreonam inhalation solution multiproduct manufacturing facility future able procure singleproduct manufacturing facility timely manner adversely affect commercial supply aztreonam inhalation solution anticipate financial result attributable product approve table content able obtain material supply necessary conduct clinical trial manufacture sell product limit ability generate revenue need access certain supply product conduct clinical trial manufacture product light economic downturn increase difficulty purchase certain raw material manufacturing process unable purchase sufficient quantity material find suitable alternate material timely manner development effort product candidate delay ability manufacture product limit limit ability generate revenue supplier key component material name nda file fda product candidate seek fda approval significant delay occur qualification new supplier require manufacturer qualified fda manufacturer continue expend time money effort area production quality control ensure compliance gmp manufacturer subject regular periodic inspection fda follow initial approval result inspection fda determine equipment facility laboratory process comply applicable fda regulation condition product approval fda suspend manufacturing operation manufacture operation single supplier product suspend unable generate sufficient quantity commercial clinical supply product meet market demand turn decrease revenue harm business addition delivery material supplier interrupt reason unable ship certain product commercial supply supply product development clinical trial addition product material utilize operation facility example manufacture ambisome fill finish macugen exclusively facilities san dimas california event natural disaster include earthquake equipment failure difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome macugen meet market need product candidate aztreonam inhalation solution pende fda approval dependent different singlesource supplier aztreonam active pharmaceutical ingredient aztreonam inhalation solution manufacture single supplier single site second administer lung patient device single supplier single site fda recently approve facility san dimas manufacture aztreonam inhalation solution subject fda approval product delivery device san dimas facility manufacturing site authorize manufacture aztreonam inhalation solution pursue fda approval party supplier fourth diluent aztreonam inhalation solution manufacture single manufacturer single site addition depend single supplier high quality cholesterol manufacture ambisome depend single supplier active pharmaceutical ingredient tablete letairis problem single supplier depend negatively impact development commercialization effort face credit risk european customer adversely affect result operation european product sale governmentowne support customer greece italy portugal spain subject significant payment delay government funding reimbursement practice result continue result increase day sale outstanding average length time account receivable outstanding account receivable country total approximately million december million day past historically receivables accumulate period time settle large lump sum payment government funding available significant change occur reimbursement practice european government government funding unavailable able collect amount customer result operation adversely affect table content product revenue gross margin reduce import country product available low price price product base local market economic competition differ country country sale country relatively high price reduce product import country low price market case pharmaceutical product sell steeply discount price develop world reexporte european country resold high price happen product particularly truvada viread agree available substantially reduce price country participate gilead access program atripla merck distribute substantially reduce price hiv infect patient develop country august agreement revenue adversely affect addition establish partnership indian generic manufacturer distribute highquality lowcost generic version tenofovir disoproxil fumarate develop world country include india generic version medication license reexporte united states europe market outside country revenue adversely affect addition purchase product country sell price relatively low resale country sell price relatively high adversely impact revenue gross margin cause sale fluctuate quarter quarter example european union require permit product purchase country sell country purchase product country sell price relatively low resale country sell price relatively high affect inventory level hold wholesaler cause relative sale level country fluctuate quarter quarter difficult forecast addition wholesaler attempt arbitrage pricing differential country purchase excessive quantity product activity result fluctuate quarterly sale certain country reflect actual demand product customer quarterly fluctuation impact earning adversely affect stock price example experience increase sale hiv product france believe portion product reexporte country resold high price sale truvada viread france country sale reexporte continue fluctuate establish order management system france december manage truvada viread sale facilitate adequate appropriate supply product commensurate market demand france assurance management system effective export activity continue france european country result result operation adversely affect country require grant compulsory license product face generic competition product number develop country government official interested group suggest pharmaceutical company drug hiv infection available low cost alternatively government develop country require grant compulsory license allow competitor manufacture sell version product reduce product sale example past certain office government brazil express concern affordability hiv product declare consider issue compulsory license permit manufacture patent product hiv infection include viread result discussion brazilian government reach agreement brazilian health ministry reduce price viread brazil approximately addition concern cost availability tamiflu relate potential avian flu pandemic generate international discussion compulsory licensing tamiflu patent example canadian government allow canadian manufacturer manufacture export active ingredient tamiflu eligible develop develop country canada access medicine regime furthermore roche issue voluntary license permit party table content manufacturing tamiflu example roche grant sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drug limited india certain develop country compulsory license issue permit generic manufacturing override tamiflu patent roche issue additional voluntary license permit party manufacturing tamiflu development reduce royalty receive roche sale tamiflu certain country permit enforcement patent party manufacturer able sell generic version product country compulsory license sale generic version product significantly reduce sale adversely affect result operation particularly generic version product import territory exist commercial sale face significant liability result product cover insurance successful claim materially reduce earning testing manufacturing marketing use commercial product product candidate development involve substantial risk product liability claim claim directly consumer healthcare provider pharmaceutical company recent year coverage availability product liability insurance decrease addition cost defend lawsuit pay damage product liability claim exceed coverage unable maintain adequate coverage claim exceed coverage financial condition ability clinically test product candidate market product adversely impact addition negative publicity associate claim regardless merit decrease future demand product impair financial condition assumption determine selfinsurance level wrong materially impact business continually evaluate level selfinsurance base historical claim experience demographic factor severity factor actuarial assumption future occurrence claim differ assumption historical trend business financial result financial condition materially impact claim expense expensive litigation government investigation reduce earning november receive notice teva pharmaceutical submit anda fda request permission manufacture market generic version truvada notice teva allege patent associate emtricitabine own emory university license exclusively invalid unenforceable andor infringe tevas manufacture use sale generic version truvada december file lawsuit district court new york teva infringement emtricitabine patent predict ultimate outcome action spend significant resource defend patent unsuccessful lawsuit original claim patent narrow invalidated patent protection truvada united states shorten expire instead addition certain officer officer name defendant class action lawsuit allege violation federal security law lawsuit dismiss united states district court northern district california august united states court appeals ninth circuit reverse dismissal remand case district court february file petition writ certiorari supreme court united states request court review judgment court appeal supreme court review petition case continue district court november receive subpoena attorney office san francisco request document market medical education program truvada viread table content emtriva cooperate continue cooperate relate governmental inquiry outcome class action lawsuit lawsuit bring investigation investigation bring inherently uncertain adverse development outcome result significant expense monetary damage penalty injunctive relief significantly reduce earning cash flow harm business change effective income tax rate reduce earning factor favorable unfavorable effect income tax rate factor include limited interpretation exist tax law change tax law rate account stock option sharebase payment merger acquisition future level rd spending change accounting standard change mix earning tax jurisdiction operate change overall level pretax earning finalization federal state foreign income tax audits impact income tax provision result mention factor significant negative impact net income income tax return audit federal state foreign tax authority currently examination internal revenue service tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction resolution exposure report period material impact result operation period change accounting affect financial position result operation generally accept accounting principle relate implementation guideline interpretation highly complex involve subjective judgment change rule interpretation adoption new pronouncement application exist pronouncement change business significantly affect financial position result operation example financial accounting standard board fasb issue fasb staff position apb accounting convertible debt instrument settle cash conversion include partial cash settlement fsp apb fsp apb address instrument commonly refer instrument c emerge issue task force issue convertible bond issuer option settle cash conversion require issuer settle principal cash conversion spread cash net share issuer option fsp apb require issuer instrument account liability equity component separately bifurcate conversion option debt instrument classify conversion option equity accrete result discount debt additional interest expense expect life debt fsp apb effective fiscal year begin december interim period fiscal year require retrospective application period present early application permit expect adoption fsp apb material impact consolidate financial position result operation base requirement fsp apb estimate fsp apb effective current comparative period report additional interest expense relate convertible senior note approximately million million million respectively addition december fasb issue statement financial accounting standard sfas revise business combination sfas r sfas r establish principle requirement recognize measure asset acquire liability assume noncontrolle interest acquiree business combination sfas r provide guidance recognize measure goodwill acquire business combination requires purchase inprocess research development table content capitalize fair value intangible asset time acquisition require acquisitionrelate expense restructure cost recognize separately business combination expand definition constitute business require acquirer disclose information user need evaluate understand financial effect business combination sfas r effective prospective basis impact business combination transaction acquisition date occur fiscal year begin december depend nature magnitude future business combination transaction sfas r material impact consolidate financial position andor result operation fail attract retain highly qualified personnel unable successfully develop new product candidate conduct clinical trial commercialize product candidate future success depend large continue ability attract retain highly qualified scientific technical management personnel personnel expertise clinical testing governmental regulation commercialization face competition personnel company university public private research institution government entity organization competition qualified personnel biopharmaceutical field intense limited pool qualified potential employee recruit able attract retain quality personnel acceptable term unsuccessful recruitment retention effort business harm item b unresolved staff comment applicable item property corporate headquarters include principal office commercial administrative research development rd facility locate foster city california january purchase approximately acre land office building locate velocity way foster city purchase building foster city lease facility foster city san dimas california house manufacturing warehousing rd activity addition lease facility durham north carolina boulder westminster colorado seattle washington house administrative rd activity international headquarter include commercial medical administrative facility locate lease london area united kingdom lease facility dublin area ireland house manufacturing distribution activity acquire manufacturing facility cork ireland september connection acquisition nycome limited transfer certain operation dublin area site facility utilize site primarily solid dose tablet manufacturing antiviral product product packaging activity manufacture facility edmonton alberta canada primarily use conduct process research scaleup clinical development candidate manufacture active pharmaceutical ingredient investigational commercial product chemical development activity improve exist commercial manufacturing process lease additional facility house commercial medical administrative activity australia austria belgium canada france germany greece italy netherlands portugal spain sweden switzerland turkey united kingdom table content believe exist property include own lease site good condition suitable conduct business believe capital resource sufficient purchase lease construct additional facility require meet expect longterm growth need item legal proceeding november receive notice teva pharmaceutical submit anda fda request permission manufacture market generic version truvada notice teva allege patent associate emtricitabine patent number own emory university license exclusively invalid unenforceable andor infringe tevas manufacture use sale generic version truvada december file lawsuit district court new york teva infringement emtricitabine patent predict ultimate outcome action spend significant resource defend patent unsuccessful lawsuit original claim patent narrow invalidated patent protection truvada united states shorten expire instead information pertain certain legal proceeding find head legal proceeding item note commitment contingency consolidate financial statement annual report incorporate reference item submission matter vote security holder matter submit vote security holder quarter end december table content ii item market registrant common equity relate stockholder matter issuer purchase equity security common stock trade nasdaq global select market symbol gild follow table set forth period indicate high low intraday sale price share common stock nasdaq global select market price represent quotation dealer adjustment retail markup markdown commission represent price actual transaction high low quarter second quarter quarter fourth quarter quarter second quarter quarter fourth quarter february share common stock outstanding hold approximately stockholder record pay cash dividend common stock inception currently expect retain earning primarily use operation expansion business anticipate pay cash dividend near future effort return value stockholder minimize dilution stock issuance board directors board authorize program repurchase common stock aggregate billion open market private block transaction pursuant rule b plan privately negotiate purchase mean note stockholder equity consolidated financial statement page annual report information repurchase program table content performance graph follow graph compare total stockholder return past year index standard poor stock index label sp index nasdaq biotechnology index label nbi index total return index assume reinvestment dividend pay company include index calculate december year composite member sp index nbi index intend use indice comparator stock performance purpose follow graph go forward composite member sp index require applicable regulation use index comparator believe nbi index relevant comparator compose peer company linesofbusiness similar stockholder return show graph necessarily indicative future performance endorse prediction future stockholder return comparison cumulative total return investment past year section soliciting material deem file sec incorporate reference filing securities act exchange act date hereof irrespective general incorporation language filing show cumulative return investment assume investment common stock nbi index sp index december table content issuer purchase equity securities october board authorize program repurchase common stock aggregate billion open market private block transaction pursuant rule b plan privately negotiate purchase mean include accelerated share repurchase transaction similar arrangement stock repurchase program expire december table summarize stock repurchase activity month end december thousands share amount maximum total number fair value share total number share purchase share average price publicly purchase purchase pay share announce programs program october october november november december december total october enter accelerate share repurchase transaction financial institution repurchase million common stock accelerate basis accelerate share repurchase billion share repurchase program authorize board october term accelerate share repurchase agreement pay million financial institution settle initial purchase transaction receive share common stock price share april subject extension certain circumstance maximum minimum share delivery provision agreement receive additional share financial institution depend average daily volume weightedaverage price common stock specify period predetermined discount share make initial payment million obligate deliver cash share financial institution certain limited circumstance case method delivery cash share common stock discretion difference total number share purchase total number share purchase publicly announce program share common stock withhold employee restrict stock award order satisfy applicable tax withholding obligation table content item select financial datum gilead sciences inc select consolidated financial datum thousand share datum year end december consolidated statement operation datum total revenue purchase inprocess research development total cost expense income loss operation gain warrant provision income taxis net income loss net income loss sharebasic share share calculationbasic net income loss sharedilute share share calculationdilute december consolidated balance sheet datum cash cash equivalent marketable security work capital total asset longterm obligation convertible senior note retain earning accumulate deficit total stockholder equity complete acquisition asset navita asset llc relate cicletanine business aggregate purchase price million allocate purchase inprocess research development iprd complete acquisition myogen inc aggregate purchase price billion billion allocate purchase iprd million allocate defer tax asset primarily related federal net operating loss tax credit carryforward certain state amortization million allocate goodwill million allocate net tangible asset acquire net asset corus pharma inc million million allocate purchase iprd million allocate net table content gilead sciences inc select consolidated financial datacontinued defer tax asset primarily related federal net operating loss tax credit carryforward certain state amortization million allocate net tangible asset million allocate assemble workforce recognize million royalty revenue relate resolution dispute f hoffmannla roche ltd hoffmannla roche inc record tax provision benefit million relate repatriation qualified foreign earning american job creation act ajca record gain million relate warrant purchase capital stock eyetech pharmaceuticals inc predecessor osi pharmaceuticals inc complete initial public offering adopt statement financial accounting standard revise sharebased payment modify prospective basis begin january note consolidated financial statement page annual report issue billion principal convertible senior note private placement enter uncollateralized million term loan agreement facilitate cash dividend distribution repatriation qualified foreign earning provision ajca table content item management discussion analysis financial condition result operation follow management discussion analysis mda intend help reader understand result operation financial condition mda provide supplement read conjunction audit consolidated financial statement accompany note consolidated financial statement disclosure include annual report include disclosure item risk factor consolidate financial statement prepare accordance generally accept accounting principle present dollar management overview biopharmaceutical company discover develop commercialize innovative therapeutic area unmet medical need mission advance care patient suffer life threaten disease worldwide headquarter foster city california operations north america europe australia market truvada emtricitabine tenofovir disoproxil fumarate atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg viread tenofovir disoproxil fumarate emtriva emtricitabine treatment human immunodeficiency virus hiv infection hepsera adefovir dipivoxil viread treatment chronic hepatitis b virus hbv ambisome amphotericin b liposome injection treatment severe fungal infection letairis ambrisentan treatment pulmonary arterial hypertension pah vistide cidofovir injection treatment cytomegalovirus infection flolan epoprostenol sodium treatment pulmonary hypertension f hoffmannla roche ltd hoffmannla roche inc roche market tamiflu oseltamivir phosphate treatment influenza royaltypaye collaborative agreement osi pharmaceuticals inc markets macugen pegaptanib sodium injection united states europe treatment neovascular agerelate macular degeneration royaltypaye collaborative agreement glaxosmithkline inc gsk markets volibris ambrisentan outside united states treatment pah royaltypaye collaborative agreement business highlight significant progress area business grow product sale significantly execute product approval product launch multiple territory progress move product candidate forward continue strengthen worldwide organization infrastructure support expand international footprint business activity commercial achievement year include continue rollout atripla european union eu drive growth atripla truvada united states canada launch viread hepatitis b eu united states make gain pah market letairis continue expansion sale marketing infrastructure include establishment new international marketing subsidiary year receive marketing authorization viread treatment chronic hepatitis b adult member states european union turkey new zealand australia united states canada marketing approval receive significant advance compound product candidate research development rd pipeline include hiv area receive positive feedback food drug administration fda year development plan elvitegravir novel integrase inhibitor hiv license japan tobacco inc gs pharmacoenhancer development boost agent certain hiv medicine single table content tablet fix dose regimen elvitegravir gs truvada fda agree proposal simultaneously develop product candidate allow eventually support separate new drug application nda filing phase clinical study study elvitegravir study single tablet fix dose regimen mention study gs result proposal combine second previously plan phase study elvitegravir phase elvitegravir study begin dose quarter hepatitis c complete dose patient continuation phase b study gs nonnucleoside polymerase inhibitor begin enrol phase study patient infect hepatitis c virus year complete phase study gs caspase inhibitor license lg life science expect initiate phase b study second quarter evaluate long term safety efficacy gs enrol patient nonalcoholic steadohepatitis phase study gs evaluate safety effect liver enzyme anticipate datum study end cardiovascular area complete enrollment phase study darusentan treatment resistant hypertension anticipate datum study second quarter continue enroll patient second phase study darusentan anticipate complete enrollment end datum available early develop cicletanine pah expect initiate phase clinical trial examine daily twice daily dose early prepare initiate phase study ambrisentan patient pulmonary hypertension idiopathic pulmonary fibrosis second quarter respiratory area submit nda aztreonam inhalation solution treatment cystic fibrosis cf fda november september receive complete response letter fda inform fda approve nda aztreonam inhalation treatment cf request additional phase clinical study november file request formal dispute resolution fda february response appeal fda notify reiterate position need conduct clinical study aztreonam inhalation solution resubmit nda submit marketing authorization application maa eu receive notice acceptance priority review health canada approval canada await response respective regulatory body respiratory area begin enrol patient noncf bronchietasis phase study evaluate aztreonam inhalation solution indication initiate phase study fourth quarter evaluate safety tolerability gs novel epithelial sodium channel blocker design increase airway hydration treatment pulmonary disease fourth quarter initiate phase study evaluating safety efficacy gs inhale coformulation fosfomycin tobramycin bacterial infection associate cf financial highlight operating result year lead total product sale billion antiviral product sale truvada atripla viread hepsera emtriva increase billion billion key driver total product sale growth compare continue uptake atripla united states product launch europe atripla contribute billion total antiviral product sale growth atripla product sale increase proportion overall product sale cause total product gross margin decrease expect primarily efavirenz component atripla sale zero gross margin truvada product sale comprise billion total antiviral product sale truvada product sale increase primarily continue sale volume growth favorable foreign currency exchange impact foreign currency fluctuation favorable impact approximately million total revenue million pretax income compare table content royalty revenue recognize collaboration corporate partner million decrease royalty revenue million decrease royalty revenue primarily decrease tamiflu sale roche relate pandemic planning initiative worldwide operating expense include rd sell general administrative sga purchase inprocess research development iprd expense increase million compare reflect increase research clinical study activity development pipeline expand commercial activity worldwide high headcount infrastructure technologyrelate cost require support continue growth business continue focus cost control operating margin continue operate margin impact efavirenz component grow atripla revenue stream decline trend tamiflu royalty cash cash equivalent marketable security increase million year drive primarily operate cash flow billion strong cash position allow complete accelerated share repurchase transaction significant common stock repurchase open market billion stock repurchase program authorize board directors board october expire december repurchase total billion stock repurchase program approximately million share december remain authorize stock repurchase board authorize stock repurchase program million light volatility development financial market continue review cash equivalent marketable security carefully invest prudently safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement continue primary importance investment goal approach help protect significant risk credit market allow meet operate cash flow requirement execute opportunity share repurchase outlook anticipate high level productivity financial performance experience continue operating objective include expansion commercial market franchise perspective leverage new international marketing subsidiary establish year reach significant rd development timeline continue strengthen pipeline internally develop andor externally inlicense purchase opportunity strengthen key alliance commercial standpoint number internal external initiative help promote continued growth franchise hiv area favorably impact presentation important data set upcoming medical conference continue test screening initiative recent change hiv treatment guideline area hepatitis b broad platform educational activity concentrate asian american community highlight need screen diagnose link patient care help support viread hbv united states launch viread hbv august hepatitis sale medical affair team concentrate effort solely promotion viread cardiovascular area continue build presence pah community support growth letairis mindful condition current macroeconomic environment affect ability achieve goal factor affect business include volatility foreign currency exchange rate government pricing pressure unite states internationally change financial health andor practice significant business partner customer see significant change continue monitor credit foreign currency exchange market table content development health care reform legislation practice supplier manufacturer corporate partner customer adjust business process need mitigate risk business success experience help maintain build financially sound business model believe allow continue expand commercial collaborative rd activity maintain infrastructure ensure quality compliance area business continue grow business achieve great operational leverage remain focused profitable revenue growth prudent expense management believe enable solid execution operating objective critical accounting policy estimate judgment discussion analysis financial condition result operation base consolidated financial statement prepare accordance generally accept accounting principle preparation financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate estimate include related revenue recognition allowance doubtful account prepay royalty clinical trial accrual tax provision stockbase compensation base estimate historical experience market specific assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate believe follow critical accounting policy reflect significant judgment estimate preparation consolidated financial statement revenue recognition product sale recognize revenue product sale persuasive evidence arrangement exist delivery customer occur price fix determinable collectibility reasonably assure record estimate reduction revenue government rebate medicaid reimbursement customer incentive cash discount prompt payment distributor fee expect return expire product estimate deduct gross product sale time revenue recognize reduction gross product sale government rebate significantly impact report net product sale base certain estimate require complex significant judgment management government rebate estimate amount payable government manage medicaid program certain qualify federal state foreign government program reimbursement portion retail price prescription fill cover program government rebate invoice directly record accrue liability consolidate balance sheet qualified program purchase product wholesaler low contractual government price wholesaler charge difference acquisition cost low price record allowance account receivable pay rebate country outside united states date payment foreign government represent significant portion total government rebate government program united states estimate sale allowance base contractual term historical utilization rate new information change program regulation guideline impact actual rebate expectation future utilization rate program product sale channel inventory datum obtain major wholesaler accordance inventory management agreement government rebate table content million million million respectively represent total gross product sale respectively deduct gross product sale base current information available actual government rebate claim period vary estimate record period december accrue government rebate million million respectively accrue liability allowance million million respectively record account receivable follow table summarize aggregate activity government rebate allowance accrue liability account balance deduct balance begin charge end year expense accrual year year end december government rebate allowance accrue liability activity relate sale activity relate sale prior total year end december government rebate allowance accrue liability activity relate sale activity relate sale prior total allowance doubtful account maintain allowance doubtful account estimate loss result inability customer require payment allowance base analysis factor include limited contractual payment term historical payment pattern customer individual customer circumstance analysis day sale outstanding customer geographic region review local economic environment potential impact government funding reimbursement practice financial condition customer economic environment operate deteriorate result inability payment additional allowance require allowance doubtful account balance percentage total account receivable materially change december december believe allowance doubtful account adequate cover anticipate loss current condition significant deterioration factor especially respect government funding reimbursement practice european market materially change expectation result increase allowance doubtful account prepay royalty capitalize royalty prepay cost specifically related emtricitabine royalty pay emory university emory hiv indication base present value future royalty obligation expect pay emory assume certain expect future level product sale incorporate emtricitabine present value future royalty obligation derive weightedaverage cost capital review quarterly expect future sale level product indicator require writedown net recoverable value asset change estimate life prepay royalty potential indicator impairment include launch significant product competitor significant deviation recognize product sale compare forecast product safety issue recall table content amortize prepay royalty base effective royalty rate derive forecast hiv product sale incorporate emtricitabine product sale forecast prepare annually determine good estimate future activity consider factor historical expect future patient usage uptake product introduction complimentary combination therapie product future product launch plan previously unanticipate significant change occur sale forecast include introduction compete product competitor hiv market emtricitabine prospectively update royalty rate amortize prepay royalty increase future royalty expense december prepay royalty asset relate emtricitabine royalty pay emory million amortization expense relate prepay royalty asset million million million year end december respectively clinical trial accrual record accrual estimate clinical study cost clinical study perform party contract research organization cro cost significant component rd expense incur cro cost million million million respectively accrue cost clinical study perform cro straightline basis service period specify contract adjust estimate require base ongoing review level effort cost actually incur cro validate accrual quarterly vendor perform detailed review activity relate significant contract base result validation process assess appropriateness accrual adjustment deem necessary ensure expense reflect actual effort incur cro generally significant portion total clinical trial cost associate start activity trial patient enrollment extensively outsource clinical trial activity usually perform small portion startup activity inhouse result cro typically perform total startup activity trial include document preparation site identification screen preparation prestudy visit training program management startup cost usually occur month contract execute milestone event drive nature remain clinical activity relate cost patient monitor administration generally occur ratably life individual contract study contract negotiate fix unit price vary length month single dose phase clinical study year complex phase clinical study average length contract upper end range order provide longterm safety efficacy datum support commercial launch truvada atripla viread hepsera emtriva letairis material cro contract terminable write notice generally liable actual effort expend cro certain noncancelable expense incur point termination amount pay advance relate uncompleted service refund contract terminate contract include additional termination payment payable terminate contract additional termination payment record probable contract terminate december difference actual estimate activity level particular study material management receive complete accurate information vendor underestimate activity level associate study give point time record additional potentially significant rd expense future period tax provision estimate income tax provision include defer tax asset liability base significant management judgment evaluate realization portion defer tax asset quarterly basis record valuation allowance reduce defer tax asset amount likely realize consider future taxable income ongoing tax planning strategy historical financial performance assess need valuation allowance table content expect realize defer tax asset previously record valuation allowance reduce valuation allowance period determination adjustment determined likely certain defer tax asset realized release related valuation allowance result credit goodwill approximately million income tax benefit approximately million million respectively future effective income tax rate affect factor change tax law regulation rate change interpretation exist law regulation impact accounting stockbase compensation change international organization change overall level income tax june financial accounting standard board fasb issue fasb interpretation accounting uncertainty income taxis fin interpretation statement financial accounting standard sfas accounting income taxis sfas fin clarifie accounting uncertainty income taxis recognize enterprise financial statement accordance sfas prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return fin provide guidance derecognition classification interest penalty account interim period disclosure transition fin effective fiscal year begin december january adopt fin increase liability unrecognized tax benefit million corresponding charge opening balance accumulate deficit permit fin addition reclassify million unrecognized tax benefit shortterm income taxis payable noncurrent defer tax asset longterm income taxis payable date adoption total federal state foreign unrecognized tax benefit million record primarily longterm income taxis payable consolidated balance sheet include accrue liability relate interest million total unrecognized tax benefit million recognize reduce effective tax rate period recognition permit provision fin continue classify interest penalty relate unrecognized tax benefit income tax provision consolidated statement operation december total federal state foreign unrecognized tax benefit million million respectively include interest million million respectively total unrecognized tax benefit december million million respectively recognize reduce effective tax rate period recognition reach agreement internal revenue service irs issue relate examination federal income tax return result reduce unrecognized tax benefit million december believe reasonably possible unrecognized tax benefit decrease approximately million month expect clarification irs certain uncertain tax position respect remain unrecognized tax benefit currently unable reasonable estimate period cash settlement respective tax authority file federal state foreign income tax return jurisdiction unite states abroad federal california income tax purpose statute limitation remain open year inception utilization net operating loss relate prior year income tax return audit federal state foreign tax authority currently examination irs tax year state foreign jurisdiction table content differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction periodically evaluate exposure associate tax filing position record liability relate uncertain tax position base fin believe currently pende item material adverse effect consolidated financial statement adverse resolution item period material impact result operation period prior adoption fin record liability relate uncertain tax position base sfas accounting contingency stockbase compensation december fasb issue sfas revise sharebased payment sfas r require sharebase payment employee director include grant stock option recognize statement operation base fair value sfas r supersede accounting principle board opinion accounting stock issue employee apb amend sfas statement cash flow january adopt sfas r modify prospective method adoption permit sfas r require compensation expense record nonveste stock option stockbase award begin quarter adoption connection adoption sfas r refined valuation assumption methodology derive assumption elect continue blackschole option valuation model fair value stock option grant prior adoption sfas r calculate multiple option approach fair value stock option grant begin january calculate single option approach concurrent adoption sfas r determined blend historical volatility imply volatility trade option stock well measure market condition expect volatility previously historical stock price volatility reliable source volatility datum estimate weightedaverage expect term stock option base historical cancellation exercise datum relate stock option contractual term vest term award record stockbase compensation expense grade vest expense attribution approach nonveste stock option grant prior adoption sfas r consistent expense attribution approach historical sfas disclosure use straightline expense attribution approach stock option grant adoption sfas r currently believe straightline expense attribution approach well reflect level service provide employee vest period award stockbase compensation expense relate stock option recognize net estimate forfeiture estimate forfeiture base historical experience result adoption sfas r recognize tax benefit stockbase compensation additional paidincapital apic incremental tax benefit realize tax attribute currently available utilize addition elect account indirect benefit stockbase compensation research tax credit extraterritorial income deduction consolidate statement operation apic year end december recognize stockbase compensation expense million million million respectively operating expense capitalize million million million respectively inventory december unrecognize stockbase compensation million relate nonveste stock option expect expense estimate weightedaverage period year management discuss development selection disclosure critical accounting policy audit committee board director audit committee review disclosure present relate critical accounting policy table content result operation total revenue total revenue billion billion billion include total revenue product sale royalty revenue contract revenue product sale product sale year consist follow thousand change change antiviral product truvada atripla viread hepsera emtriva total antiviral product ambisome letairis total product sale total product sale increase compare primarily overall increase antiviral product sale include strong growth atripla sale continue growth truvada sale foreign currency denominate product sale experience net benefit depreciation dollar approximately million compare total product sale increase compare primarily increase total product sale volume billion favorable foreign currency exchange impact million significant percentage product sale continue denominate foreign currency foreign currency forward option contract hedge percentage forecast international sale primarily denominate euro reduce eliminate fluctuation sale change foreign currency exchange rate see net benefit mention antiviral product antiviral product sale increase compare compare drive primarily sale volume growth atripla truvada favorable foreign currency exchange impact truvada truvada sales increase compare drive primarily sale volume growth united states europe favorable foreign currency exchange impact truvada sale increase compare drive primarily strong sale volume growth europe favorable foreign currency exchange environment truvada sale account total antiviral product sale respectively atripla atripla sale increase compare drive primarily continue uptake atripla united states launch product european country atripla sale increase compare primarily year atripla sale table content atripla launch united states july continue strong uptake atripla united states consolidate atripla product sale primary beneficiary joint venture bristol myerssquibb company bms united states outside united states recognize atripla product sale efavirenz portion atripla sale approximately million million million respectively atripla sale account total antiviral product sale respectively sale atripla european union significant atripla approve sale european union december antiviral product antiviral product sale include product sale viread hepsera emtriva increase compare drive primarily increase hepsera sale benefit favorable foreign currency impact sale volume growth certain european country antiviral product sale decrease compare drive primarily decrease sale viread emtriva respectively impact patient switch viread emtriva contain regimen regimen contain truvada andor atripla country combination product available partially offset increase hepsera sale primarily sale volume growth major geographical region favorable foreign currency exchange environment ambisome sale ambisome increase compare primarily favorable foreign currency exchange impact sale volume growth certain european market sale ambisome increase compare primarily sale volume growth europe favorable foreign currency exchange impact ambisome product sale united states relate solely sale ambisome astellas pharma inc record manufacturing cost letairis sale letairis treatment pah increase compare drive primarily sale volume growth united states letairis launch june expect total product sale continue grow continue expand sale marketing effort royalty revenue follow table summarize period period change royalty revenue thousand change change royalty revenue significant source royalty revenue sale tamiflu f hoffmannla roche ltd hoffmannla roche inc roche royalty revenue million decrease compare drive primarily recognition tamiflu royalty roche million compare tamiflu royalty roche million low tamiflu royalty primarily decrease roche sale relate pandemic planning initiative worldwide royalty revenue million increase compare drive primarily recognition high tamiflu royalty roche compare million record high tamiflu royalty table content high tamiflu sale record roche include sale relate pandemic planning initiative worldwide recognize royalty tamiflu sale roche quarter follow quarter tamiflu sell cost good sell product gross margin follow table summarize period period change product sale thousand cost good sell thousand product gross margin change change total product sale cost good sell product gross margin product gross margin compare decrease product gross margin primarily grow proportion atripla sale include efavirenz portion zero product gross margin impact change product geographic mix product sale high mix atripla product sale decrease overall product gross margin record atripla product sale benefit product gross margin truvada portion atripla sale efavirenz portion atripla sale carry zero product gross profit gross margin purchase efavirenz bms bmss net selling price efavirenz expect product gross margin lower compare primarily high expect atripla sale research development expense follow table summarize period period change major component rd expense thousand change change research clinical development pharmaceutical development total research development rd expense consist primarily personnel cost include salary benefit stockbase compensation clinical study perform cro material supply license fee overhead allocation consist support facility relate cost rd activity separate main category research clinical development pharmaceutical development research cost typically consist preclinical toxicology cost clinical development cost include cost phase clinical trial pharmaceutical development expense consist cost product formulation chemical analysis rd expense increase million compare primarily increase clinical study expense million primarily antiviral cardiovascular area increase compensation benefit expense million primarily high headcount rd expense increase million compare primarily increase compensation benefit expense million largely high headcount increase clinical study table content expense million increase contract service expense million relate clinical product development research activity cardiovascular program addition pay million upfront license fee lg life sciences ltd lgl million license relate fee pari gmbh pari expense future alternative use technology general significant collaboration payment like lgls pari cause rd expense fluctuate period period expect rd expense increase level increase spending internal collaborative rd effort anticipate progress product candidate advance clinical study add clinical development program pipeline sell general administrative expense follow table summarize period period change sga expense year thousand change change sell general administrative sga expense increase million compare primarily increase compensation benefit expense million largely high headcount increase marketing promotional expense million support expand commercial operation increase consulting support service expense million relate growth business cost million associate certain employee termination relate dispute international operation increase infrastructure technology expense million increase compare partially offset decrease stockbase compensation expense million primarily high expense associate unvested stock option assume myogen include accelerate stockbased compensation expense relate certain myogen employee termination sga expense increase million compare increase primarily increase compensation benefit expense million largely high headcount increase market promotional expense million antiviral cardiovascular area include related launch letairis treatment pah expect sga expense remain essentially consistent sga expense believe organizational geographic expansion activity provide appropriate infrastructure support business purchase inprocess research development expense connection acquisitions myogen inc myogen corus pharma inc corus record purchase iprd expense billion million respectively year end december table content purchase iprd expense myogen represent estimate fair value myogen incomplete rd program reach technological feasibility alternative future use acquisition date expense acquisition summary program acquisition date update subsequent change status development follow estimate acquisition date fair value program description status development millions ambrisentan orally active nonsulfonamide propanoic phase clinical trial complete prior acidclass endothelin receptor antagonist acquisition date file nda fda era treatment pah december june fda approve letairis treatment pah united states additionally march european medicine agency emea validate marketing authorization application ambrisentan treatment pah file collaboration partner gsk april european commission grant gsk marketing authorization ambrisentan treatment pah market volibris gsk darusentan orally active etaselective era phase clinical development acquisition treatment resistant hypertension date date filing estimate fair value purchase iprd determine income approach discount expect future cash flow present value estimate fair value purchase iprd present value discount rate base estimate internal rate return myogen operation comparable estimate weightedaverage cost capital company myogen profile represent rate market participant use value purchase iprd compensate differ phase development ambrisentan darusentan probabilityadjuste estimation expect future cash flow associate program determine time present value expect future cash flow discount rate project cash flow ambrisentan darusentan program base key assumption estimate revenue operate profit relate program consider stage development time resource need complete development approval relate product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop drug compound obtain fda regulatory approval risk relate viability potential alternative treatment future target market purpose estimate fair value ambrisentan program estimate program approximately complete acquisition date base estimate time cost complete phase clinical trial complete acquisition date estimate incur future rd cost approximately million million date acquisition include year commercialization expect occur material net cash inflow estimate begin ambrisentan assume necessary regulatory approval received product successfully commercialize date table content purpose estimate fair value darusentan program estimate program approximately complete acquisition date base estimate time cost complete remain effort include completion phase clinical development prepare filing nda fda acquisition date estimate incur future rd cost approximately million million date acquisition include year commercialization expect occur material net cash inflow estimate begin darusentan assume necessary regulatory approval received product successfully commercialize date remain effort complete darusentan iprd program consist primarily clinical trial cost length success extremely difficult predict obtain necessary regulatory approval numerous risk uncertainty exist prevent completion development include possibility unfavorable result clinical trial risk fail obtain fda regulatory body approval feedback regulatory authority result clinical trial require modification delay later stage clinical trial additional trial perform certain darusentan treatment resistant hypertension approve united states country outside united states marketing approval significant limitation use future discussion regulatory agency determine datum need timeline review differ materially current projection darusentan successfully commercialize result strategic decision discontinue development darusentan example believe commercialization difficult relative opportunity pipeline program complete timely basis prospect future revenue growth adversely impact assurance give underlie assumption forecast cash flow timely successful completion project materialize estimate reason actual result vary significantly estimate result purchase iprd expense corus represent estimate fair value coruss incomplete aztreonam inhalation solution cf rd program reach technological feasibility alternative future use acquisition date expense acquisition description program acquisition date update subsequent change status development follow estimate acquisition date fair value program description status development million aztreonam inhalation aztreonam formulation phase clinical trial acquisition date file nda solution inhalation fda november september receive complete treatment cf gramnegative bacteria response letter fda inform fda approve cause lung infection patient nda aztreonam inhalation solution treatment cf cf current form request conduct additional phase clinical study november file request formal dispute resolution fda february response appeal fda notify reiterate position need conduct clinical study aztreonam inhalation solution resubmit nda submit marketing authorization application european union receive notice acceptance priority review health canada approval canada await response respective regulatory body table content estimate fair value purchase iprd determine income approach discount expect future cash flow present value estimate fair value purchase iprd present value discount rate base estimate internal rate return coruss operation comparable estimate weightedaverage cost capital company coruss profile represent rate market participant use value purchase iprd project cash flow aztreonam inhalation solution program base key assumption estimate revenue operate profit relate program consider stage development time resource need complete development approval relate product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop drug compound obtain fda regulatory approval risk relate viability potential alternative treatment future target market coruss early stage candidate include valuation purchase iprd early stage project identifiable revenue expense associate purpose estimate fair value aztreonam inhalation solution program estimate program approximately complete acquisition date base estimate time cost complete remain effort include completion phase clinical development prepare filing nda fda acquisition date estimate incur future rd cost approximately million million date acquisition include year commercialization expect occur material net cash inflow estimate begin aztreonam inhalation solution program assume necessary regulatory approval received product successfully commercialize date remain effort complete coruss iprd program consist primarily clinical trial cost length success extremely difficult predict numerous risk uncertainty exist prevent completion development include possibility unfavorable result clinical trial risk fail obtain fda regulatory body approval certain aztreonam inhalation solution treatment cf approve united states country outside united states marketing approval significant limitation use aztreonam inhalation solution treatment cf successfully commercialize result strategic decision discontinue development aztreonam inhalation solution treatment cf example believe commercialization difficult relative opportunity pipeline program complete timely basis prospect future revenue growth adversely impact assurance give underlie assumption forecast cash flow timely successful completion project materialize estimate reason actual result vary significantly estimate result connection acquisition cicletanine asset navita asset llc record purchase iprd expense million consider acquisition material transaction disclosure relate purchase iprd interest income net record interest income net million million million respectively decrease compare primarily increase cost relate hedging activity million net foreign currency loss million decrease interest income million primarily low interest rate partially offset writedown certain security record mention decrease compare primarily attributable low average cash investment balance writedown million million relate otherthantemporary impairment investment achillion pharmaceuticals inc assetbacked commercial paper structure investment vehicle respectively table content provision income taxis provision income taxis million million million respectively effective tax rate differ federal statutory rate primarily tax credit resolution certain tax position tax authority certain operating earning nonus subsidiary consider indefinitely invest outside united states offset state taxis effective tax rate differ federal statutory rate primarily tax credit certain operating earning nonus subsidiary consider indefinitely invest outside united states offset state taxis include operate income pretax charge million billion purchase iprd expense associate corus myogen acquisition respectively record income tax benefit relate purchase iprd expense amount nondeductible effective tax rate differ federal statutory rate primarily tax credit certain operating earning nonus subsidiary consider indefinitely invest outside united states offset federal tax nondeductible purchase iprd expense state taxis june fasb issue fin clarifie accounting uncertainty income taxis recognize enterprise financial statement accordance sfas prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return fin provide guidance derecognition classification interest penalty account interim period disclosure transition fin effective fiscal year begin december january adopt fin increase liability unrecognized tax benefit million corresponding charge opening balance accumulate deficit permit fin addition reclassify million unrecognized tax benefit shortterm income taxis payable noncurrent defer tax asset longterm income taxis payable date adoption total federal state foreign unrecognized tax benefit million record primarily longterm income taxis payable consolidated balance sheet include accrue liability relate interest million total unrecognized tax benefit million recognize reduce effective tax rate period recognition permit provision fin continue classify interest penalty relate unrecognized tax benefit income tax provision consolidated statement operation december total federal state foreign unrecognized tax benefit million million respectively include interest million million respectively total unrecognized tax benefit december million million respectively recognize reduce effective tax rate period recognition reach agreement irs issue relate examination federal income tax return result reduce unrecognized tax benefit million december believe reasonably possible unrecognized tax benefit decrease approximately million month expect clarification irs certain uncertain tax position respect remain unrecognized tax benefit currently unable reasonable estimate period cash settlement respective tax authority table content liquidity capital resource follow table summarize cash cash equivalent marketable security work capital cash flow activity end year thousand december cash cash equivalent marketable security working capital year end december cash provide operating activity invest activity financing activity cash cash equivalent marketable security cash cash equivalent marketable security total billion december increase million december increase primarily attributable net cash provide operation billion proceed issuance common stock employee stock plan million increase partially offset repurchase billion common stock stock repurchase program cash cash equivalent marketable security total billion december increase billion december increase billion primarily attributable net cash provide operation billion proceed issuance stock employee stock plan million increase partially offset repurchase million common stock stock repurchase program repayment remain amount term loan million capital expenditure million relate expansion facility accommodate growth work capital work capital december billion increase million december increase primarily attributable increase million inventory primarily purchase efavirenz estimate market value efavirenz bms increase million account receivable net drive primarily increase product sale million increase cash cash equivalent shortterm marketable security increase partially offset million increase account payable primarily purchase efavirenz estimate market value sustiva bms table content work capital december billion compare billion december significant factor result increase work capital million increase cash cash equivalent shortterm marketable security primarily cash provide operating activity proceed issuance common stock employee stock plan partially offset repurchase common stock stock repurchase program repayment term loan capital spend million increase prepay taxis relate intercompany profit parent company joint venture million increase account receivable net primarily increase sale cash provide operating activity cash provide operating activity billion primarily related net income billion adjust noncash item million tax benefit employee stock plan million stockbase compensation expense partially offset million excess tax benefit stock option exercise reclassify cash provide financing activity accordance sfas r million cash outflow relate change operate asset liability cash provide operating activity billion comprise primarily billion net income adjust noncash item million stockbase compensation expense million defer income taxis million tax benefit relate employee stock plan million excess tax benefit stock option exercise partially offset million net cash outflow relate change operate asset liability cash provide operating activity billion comprise primarily billion net loss adjust noncash item billion purchase iprd expense stockbase compensation expense million million tax benefit relate employee stock plan million excess tax benefit stock option exercise partially offset million net cash outflow relate change operate asset liability cash investing activity cash investing activity primarily relate purchase sale maturity availableforsale security capital expenditure cash investing activity primarily relate purchase sale maturity availableforsale security capital expenditure acquisition nycome limited cash investing activity primarily relate purchase sale maturity availableforsale security acquisition myogen raylo chemicals inc raylo corus capital expenditure million cash investing activity compare billion decrease primarily cash financing activity compare fund stock repurchase billion cash investing activity compare billion decrease million decrease primarily acquisition myogen raylo corus total billion cash purchase sale maturity marketable security activity compare capital expenditure related primarily expansion manufacturing capability upgrade facility spending computer laboratory equipment enterprise table content software accommodate continued business growth capital expenditure include construction new building foster city california headquarters capital expenditure include purchase building previously lease construction cost new building foster city california headquarters december capital expenditure commitment million include purchase office building land aircraft construct delivery discuss expect fulfill commitment fund generate operating cash flow october sign purchase sale agreement purchase office building approximately acre land locate foster city california aggregate purchase price approximately million initial refundable deposit million escrow october january remain balance million pay escrow closing transaction closing purchase sale agreement amend allow holdback escrow million purchase price release depend outcome certain requirement mutually agree closing august result review term exist corporate aircraft lease consideration alternative available expiration enter agreement purchase aircraft construct delivery aggregate purchase price purchase agreement million december deposit total million record noncurrent asset consolidate balance sheet future deposit term purchase agreement follow million million million million million option terminate purchase agreement subject maximum payment fully equip price aircraft cash provide financing activity cash financing activity billion drive primarily billion repurchase common stock stock repurchase program cash outflow partially offset proceed million receive issuance common stock employee stock plan million excess tax benefit stock option exercise october board authorize program repurchase common stock aggregate billion open market private block transaction pursuant rule b plan privately negotiate purchase mean stock repurchase program expire december stock repurchase program repurchase share open market enter structured accelerated share repurchase transaction party describe february enter accelerated share repurchase agreement financial institution repurchase million common stock accelerate basis term accelerate share repurchase agreement financial institution pay million financial institution settle initial purchase transaction receive share common stock price share june maturity agreement accordance share delivery provision agreement receive additional share common stock base average daily volume weightedaverage price common stock specify period predetermined discount share result final purchase price common stock accelerate share repurchase share october enter accelerate share repurchase transaction financial institution repurchase million common stock accelerate basis term accelerate share repurchase agreement financial institution pay million financial institution settle initial purchase transaction receive share common stock price share april subject extension certain circumstance maximum minimum share delivery provision agreement receive additional share financial institution depend average daily volume weightedaverage price common stock table content specify period predetermined discount share make initial payment million obligate deliver cash share financial institution certain limited circumstance case method delivery cash share common stock discretion december remain authorize stock repurchase stock repurchase program expire december million cash financing activity million drive primarily million repurchase common stock stock repurchase program million pay remain amount term loan partially offset proceed issuance stock employee stock plan million million excess tax benefit stock option exercise cash provide financing activity million drive primarily million net proceed generate issuance convertible senior note note convertible senior note note collectively note relate transaction addition receive proceed issuance stock employee stock plan million million excess tax benefit employee stock option exercise cash inflow partially offset million principal repayment term loan information december whollyowne subsidiary gilead biopharmaceutics ireland corporation gbic enter amend restate credit agreement supersede exist revolve credit agreement syndicate bank increase credit facility billion amend restate credit agreement include subfacility swingline loan letter credit term amend restate credit agreement borrow initially aggregate billion revolving credit loan loan amend restate credit agreement bear interest libor plus margin range basis point basis point ii base rate define amend restate credit agreement prepay outstanding borrowing time penalty premium outstanding interest principal payable december connection amend restate credit agreement enter parent guaranty agreement guarantee obligation gbic amend restate credit agreement expect use proceed loan amend restate credit agreement work capital requirement general corporate purpose december million letter credit outstanding amend restate credit agreement believe exist capital resource supplement cash generate operation adequate satisfy capital need foreseeable future future capital requirement depend factor include limited follow commercial performance current future product progress scope rd effort include preclinical study clinical trial cost timing outcome regulatory review expansion sale marketing capability administrative expense possibility acquire additional manufacturing capability office facility possibility acquire company new product establishment additional collaborative relationship company cost associate defense settlement adverse result litigation government investigation table content future require additional funding form proceed equity debt financing fund require assure available favorable term balance sheet arrangement balance sheet arrangement currently material reasonably likely material consolidated financial position result operation contractual obligation contractual obligation consist debt obligation operating lease purchase obligation primarily form capital commitment purchase obligation active pharmaceutical ingredient inventory relate item clinical trial contract follow table summarize significant enforceable legally bind obligation future commitment obligation relate contract likely continue regardless fact certain obligation cancelable december thousands payment period contractual obligation total year year year year convertible senior note operate lease obligation capital commitment purchase obligation clinical trial total december outstanding principal billion note issue april december firm capital project commitment approximately million primarily relate expansion facility infrastructure purchase commitment corporate aircraft construct delivery december firm purchase commitment relate active pharmaceutical ingredient certain inventory relate item amount related active pharmaceutical ingredient represent minimum purchase requirement actual purchase expect significantly exceed amount addition commit potential future milestone payment party license development program payment agreement generally payable achievement certain developmental regulatory andor commercial milestone achievement milestone probable reasonably estimable contingency record consolidated balance sheet include table december clinical study clinical trial phase significant clinical trial expenditure cro contract cro cancelable generally cancel contract amount reflect commitment base exist contract reflect future modification termination exist contract anticipate potential new contract total gross unrecognized tax benefit liability million december believe reasonably possible unrecognized tax benefit decrease approximately million month expect clarification irs certain uncertain tax table content position respect remain unrecognized tax benefit currently unable reasonable estimate period cash settlement respective tax authority amount include longterm income taxis payable longterm defer tax asset consolidate balance sheet include table recent accounting pronouncement june fasb ratify eitf issue determine instrument embed feature index entitys stock eitf eitf provide guidance determine certain instrument embed feature consider indexed stock include instrument similar note convertible note hedge warrant purchase stock forward contract enter accelerate share repurchase transaction february complete june forward contract enter accelerate share repurchase transaction october eitf require company use twostep approach evaluate instrument contingent exercise provision settlement provision determine instrument consider index stock exempt application sfas accounting derivative instrument hedge activity eitf effective fiscal year begin december outstanding instrument date adoption require retrospective application accounting cumulative effect adjustment retain earning adoption expect adoption eitf material impact consolidate financial position result operation fasb issue fsp apb accounting convertible debt instrument settle cash conversion include partial cash settlement fsp apb fsp apb address instrument commonly refer instrument c eitf require issuer settle principal cash conversion spread cash net share issuer option fsp apb require issuer instrument account liability equity component separately bifurcate conversion option debt instrument classify conversion option equity accrete result discount debt additional interest expense expect life debt fsp apb effective fiscal year begin december interim period fiscal year require retrospective application period present early application permit expect adoption fsp apb material impact consolidate financial position result operation base requirement fsp apb estimate fsp apb effective current comparative period report additional interest expense relate note approximately million million million respectively december fasb issue sfas noncontrolle interest consolidate financial statement amendment accounting research bulletin consolidated financial statement sfas sfas establish accounting reporting standard ownership interest subsidiary hold party parent consolidate net income loss attributable parent noncontrolle interest change parent ownership interest valuation retain noncontrolle equity investment subsidiary deconsolidate sfas establish additional reporting requirement identify distinguish ownership interest parent interest noncontrolle owner sfas effective interim period fiscal year begin december adopt sfas plan reclassify noncontrolle interest minority interest consolidate balance sheet liability stockholder equity present noncontrolle interest minority interest consolidate statement operation net income attributable noncontrolle interest component total consolidated net income loss december fasb issue sfas revise business combination sfas r sfas r establish principle requirement recognize measure asset acquire liability assume noncontrolle interest acquiree business combination sfas r provide table content guidance recognize measure goodwill acquire business combination requires purchase iprd capitalize fair value intangible asset time acquisition require acquisitionrelate expense restructure cost recognize separately business combination expand definition constitute business require acquirer disclose information user need evaluate understand financial effect business combination sfas r effective prospective basis impact business combination transaction acquisition date occur december depend nature magnitude future business combination transaction sfas r material impact consolidate financial position andor result operation item quantitative qualitative disclosure market risk foreign currency exchange risk operation include manufacture sale activity united states canada ireland sale activity country outside united states include europe australia result financial result significantly affect factor change foreign currency exchange rate weak economic condition foreign market distribute product operating result expose change foreign currency exchange rate dollar foreign currency significant euro dollar strengthen currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative amount sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business significant percentage product sale denominate foreign currency enter foreign currency exchange forward contract foreign currency exchange option contract partially mitigate impact change currency exchange rate net cash flow foreign currency denominate sale hedge certain monetary asset liability denominate foreign currency reduce eliminate exposure currency fluctuation date transaction record date cash collect pay general market risk contract offset correspond gain loss transaction hedge recent year foreign currency exchange fluctuation primarily positive impact product sale gross margin impact foreign currency fluctuation moderate hedging program table content follow table summarize notional amount weightedaverage currency exchange rate fair value open foreign currency exchange forward option contract december contract maturity month weightedaverage rate state term dollar foreign currency fair value represent estimate settlement amount december notional amount fair value dollar thousand foreign currency exchange forward contract weight average notional settlement currency price fair value euro british pound australian dollar danish krone norwegian krone swiss franc total foreign currency exchange option contract weight average notional strike currency price fair value british pound euro australian dollar total total foreign exchange forward option contract total notional billion total fair value relate net asset million open foreign currency exchange forward option contract december compare total notional billion total fair value relate net liability million open foreign currency exchange forward contract december interest rate risk portfolio availableforsale marketable security fix variable rate liability create exposure interest rate risk respect investment portfolio adhere investment policy require limit amount invest security base duration industry group investment type issuer security issue government goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return table content follow table summarize expect maturity average interest rate interest generate asset interestbeare liability december dollar thousand year end december total fair value december asset availableforsale debt security average interest rate liability convertible senior note average interest rate april issue million principal convertible senior note note million principal convertible senior note note private placement pursuant rule securities act amend note note issue par bear interest rate respectively convert subject certain circumstance credit risk portion marketable security hold auction rate security begin observe fail auction auction rate security underlie asset comprise student loan december hold approximately million auction rate security availablefor sale longterm marketable security underlie asset comprise student loan auction rate security comprise approximately total cash cash equivalent marketable security december auction rate security include subject fail auction currently rate aaa consistent high quality rating require investment policy auction continue fail security invest unable liquidate auction rate security par need desire access fund invest security believe base total cash marketable security position expect operating cash flow access fund credit facility able hold security recovery auction market final maturity result anticipate current illiquidity auction rate security material effect cash requirement work capital light volatility development see financial market continue review cash equivalent marketable security carefully invest prudently believe maintain primary goal investment policy safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement protect risk credit market allow continue meet operate cash flow requirement execute opportunity million million accelerated share repurchase account receivable balance december billion compare million december growth account receivable balance primarily high product sale antiviral product united states europe european product sale government own support customer greece italy portugal spain subject significant payment delay government funding reimbursement practice result continue result increase day sale outstanding average length time account receivable outstanding turn increase credit risk relate certain customer sale customer country europe tend pay relatively slowly increase continue increase average length time account receivable outstanding december account receivable greece italy portugal spain total million million day past table content date experience significant loss respect collection account receivable believe substantially account receivable balance collectible perform credit evaluation customer financial condition generally require collateral item financial statement supplementary datum financial statement require item set forth begin report incorporate reference item change disagreement accountant account financial disclosure applicable item control procedure evaluation disclosure control procedure evaluation december carry supervision participation management include chief executive officer chief financial officer effectiveness design operation disclosure control procedure define security exchange sec rule control procedure company design ensure information require disclose company report file submit securities exchange act amended exchange act record process summarize report time period specify sec rule form base evaluation chief executive officer chief financial officer conclude disclosure control procedure effective b management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define exchange act rule af internal control system design provide reasonable assurance preparation fair presentation financial statement external purpose accordance generally accept accounting principle internal control system matter design inherent limitation provide reasonable assurance objective internal control system meet supervision participation management include chief executive officer chief financial officer conduct evaluation effectiveness internal control financial reporting base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission coso base evaluation conclude internal control financial reporting effective december independent register public accounting firm ernst young llp audit consolidated financial statement include annual report issue report effectiveness internal control financial reporting december report audit internal control financial reporting appear table content report independent register public accounting firm board director stockholder gilead sciences inc audit gilead sciences inc internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso criterion gilead sciences incs management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion gilead sciences inc maintain material respect effective internal control financial reporting december base coso criterion audit accordance standard public company accounting oversight board united states consolidated financial statement gilead sciences inc report date february express unqualified opinion thereon ernst young llp palo alto california february table content c change internal control financial reporting management include chief executive officer chief financial officer evaluate change internal control financial reporting occur quarter end december conclude change quarter materially affect reasonably likely materially affect internal control financial reporting item b information applicable iii item director executive officer corporate governance information require item concern director executive officer incorporate reference section definitive proxy statement file sec pursuant regulation connection annual meeting stockholder proxy statement heading nominee board committee meeting executive officer section beneficial ownership reporting compliance write code ethic apply director employee include executive officer include limitation principal executive officer principal financial officer principal accounting officer controller person perform similar function code ethic available website httpwwwgileadcom investor section corporate governance change waiver code ethic disclose website intend satisfy disclosure requirement item form k amendment waiver provision code ethic disclose information website item executive compensation information require item incorporate reference section proxy statement heading executive compensation compensation committee interlock insider participation compensation committee report compensation nonemployee board member item security ownership certain beneficial owner management relate stockholder matter information require item incorporate reference section proxy statement heading security ownership certain beneficial owner management security authorize issuance equity compensation plan item certain relationship relate transaction director independence information require item incorporate reference section proxy statement heading nominee certain relationship relate party transaction item principal accountant fee service information require item incorporate reference section proxy statement head principal accountant fee service table content iv item exhibit financial statement schedule follow document file annual report index list consolidate financial statement report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement operation consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement schedule ii include report schedule omit require require information include financial statement note thereto exhibit follow exhibit file herewith incorporate reference exhibit exhibit footnote number description document restate certificate incorporation registrant certificate designation series junior participate prefer stock registrant certificate amendment certificate designation series junior participate prefer stock registrant amend restate bylaw registrant amend restate october reference exhibit exhibit exhibit exhibit amend restate right agreement registrant chasemellon shareholder services llc date october amendment amend restate right agreement registrant mellon investor service llc know chasemellon shareholder services llc date october second amendment amend restate right agreement registrant mellon investor service llc know chasemellon shareholder services llc date indenture relate convertible senior note registrant wells fargo bank national association trustee include form convertible senior note date april indenture relate convertible senior note registrant wells fargo bank national association trustee include form convertible senior note date april table content exhibit exhibit footnote number description document confirmation otc convertible note hedge relate note date april amend restate april registrant bank america na confirmation otc convertible note hedge relate note date april amend restate april registrant bank america na confirmation otc warrant transaction date april amend restate april registrant bank america na warrants expire confirmation otc warrant transaction date april amend restate april registrant bank america na warrants expire amend restate credit agreement registrant gilead biopharmaceutics ireland corporation lender party thereto bank america na administrative agent swing line lender lc issuer date december parent guaranty agreement date december registrant master confirmation registrant citibank na supplemental confirmation date october gilead sciences inc stock option plan amend january form option agreement stock option plan gilead sciences inc nonemployee directors stock option plan amend january form option agreement gilead sciences inc nonemployee directors stock option plan gilead sciences inc equity incentive plan amend form employee stock option agreement equity incentive plan grant prior february form employee stock option agreement equity incentive plan grant commence february form nonemployee director stock option agreement equity incentive plan grant prior form nonemployee director option agreement equity incentive plan initial grant commence form nonemployee director option agreement equity incentive plan annual grant commencing form performance share award agreement equity incentive plan grant form performance share award agreement equity incentive plan grant commence form restrict award agreement equity incentive plan grant prior form restrict stock unit issuance agreement equity incentive plan grant commence table content exhibit exhibit footnote number description document gilead sciences inc employee stock purchase plan amend gilead sciences inc defer compensation planbasic plan document gilead sciences inc defer compensation planadoption agreement addendum gilead sciences inc defer compensation plan gilead sciences inc defer compensation plan amend restate october gilead sciences inc severance plan amend december gilead sciences inc corporate bonus plan gilead sciences inc code section bonus plan base salary name executive officer offer letter date october registrant caroline dorsa offer letter date april registrant robin washington form indemnity agreement enter registrant director executive officer form employee proprietary information invention agreement enter registrant certain officer key employee form employee proprietary information invention agreement enter registrant certain officer key employee revise september amend restate collaboration agreement registrant gilead holding llc bristolmyers squibb company er squibb son llc bristolmyers squibb gilead sciences llc date september commercialization agreement gilead sciences limited bristolmyers squibb company date december letter agreement registrant institute organic chemistry biochemistry academy sciences czech republic iocb rega stichting vzw rega iocb iocbrega date september amendment agreement registrant iocbrega date october amendment agreement registrant iocbrega date december sixth amendment agreement license agreement iocb k u leuven research development registrant date august development license agreement registrant f hoffmannla roche ltd hoffmannla roche inc date september amendment supplement date november development licensing agreement registrant f hoffmann la roche ltd hoffmanla roche inc date september exclusive license agreement registrant successor triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university date royalty sale agreement registrant emory university investor trust custodial service ireland limit solely capacity trustee royalty pharma date july table content exhibit exhibit footnote number description document amend restate license agreement registrant emory university investor trust custodial service ireland limit solely capacity trustee royalty pharma date july license agreement japan tobacco inc registrant date march license agreement registrant successor myogen inc abbott deutschland holding gmbh date october license agreement registrant successor myogen inc abbott laboratories date june master clinical commercial supply agreement gilead world market limited registrant patheon inc date january tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd date july addendum tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd date addendum tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd date december tenofovir disoproxil fumarate manufacture supply agreement registrant ampac fine chemical llc date march restate amend toll manufacturing agreement gilead sciences limited registrant altana pharma oranienburg gmbh date november emtricitabine manufacturing supply agreement gilead sciences limited degussa ag date june purchase sale agreement escrow instruction electronics imaging inc registrant date october amend subsidiary registrant consent independent register public accounting firm power attorney reference signature certification chief executive officer require rule aa rule da securities exchange act amend certification chief financial officer require rule aa rule da securities exchange act amend certification chief executive officer chief financial officer require rule ab rule db section chapter title united states code usc file exhibit registrant current report form k file incorporate reference file exhibit registrant current report form k file november incorporate reference file exhibit registrant current report form k file incorporate reference file exhibit registrant current report form k file october incorporate reference file exhibit registrant current report form k file october incorporate reference table content file exhibit registrant current report form k file october incorporate reference file exhibit registrant registration statement form file june incorporate reference file exhibit registrant current report form k file april incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant current report form k file december incorporate reference file exhibit registrant current report form k file october incorporate reference file exhibit registrant registration statement form file january incorporate reference file exhibit registrant registration statement form amend incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant current report form ka file february incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant quarterly report form q quarter end march incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit registrant current report form k file december incorporate reference file exhibit registrant current report form k file incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference information include registrant current report form k file january incorporate reference file exhibit registrant annual report fiscal year end march incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit triangle pharmaceutical inc quarterly report form qa file november incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit registrant quarterly report form q quarter end march incorporate reference file exhibit myogen inc registration statement form amend originally file august incorporate reference table content file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant current report form k file august incorporate reference management contract compensatory plan arrangement certification accompanie relate deem file security exchange commission incorporate reference file registrant security act amend securities exchange act amend date irrespective general incorporation language contain file certain confidential portion exhibit omit mean mark portion asterisk mark exhibit file separately secretary sec mark pursuant registrant application request confidential treatment rule b securities exchange act amend table content gilead sciences inc consolidated financial statement year end december content report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement operation consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement table content report independent register public accounting firm board director stockholder gilead sciences inc audit accompany consolidated balance sheet gilead sciences inc december relate consolidated statement operation stockholder equity cash flow year period end december audits include financial statement schedule list index item financial statement schedule responsibility company management responsibility express opinion financial statement schedule base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statement refer present fairly material respect consolidate financial position gilead sciences inc december consolidate result operation cash flow year period end december conformity generally accept accounting principle opinion relate financial statement schedule consider relation basic financial statement take present fairly material respect information set forth audit accordance standard public company accounting oversight board united states gilead sciences inc internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion thereon ernst young llp palo alto california february table content gilead sciences inc consolidated balance sheet thousand share amount december asset current asset cash cash equivalent shortterm marketable security account receivable net allowance december december inventory defer tax asset prepay taxis prepaid expense current asset total current asset property plant equipment net noncurrent portion prepay royalty noncurrent defer tax asset longterm marketable security noncurrent asset total asset liability stockholder equity current liability account payable accrue government rebate accrue compensation employee benefit accrue royalty income taxis payable accrue liability defer revenue current portion longterm obligation total current liability longterm defer revenue convertible senior note longterm income taxis payable longterm obligation minority interest commitment contingency note stockholder equity prefer stock par value share share authorize outstanding common stock par value share share authorize share issue outstanding december respectively additional paidin capital accumulate comprehensive income loss retain earning total stockholder equity total liability stockholder equity accompany note table content gilead sciences inc consolidated statement operation thousand share amount year end december revenue product sale royalty revenue contract revenue total revenue cost expense cost good sell research development sell general administrative purchase inprocess research development total cost expense income loss operation interest income net interest expense minority interest income loss provision income taxis provision income taxis net income loss net income loss sharebasic share share calculationbasic net income loss sharedilute share share calculationdilute accompany note table content gilead sciences inc consolidated statement stockholder equity thousand common stock accumulate retain additional defer earning total paidin comprehensive stock accumulate stockholder share capital income loss compensation deficit equity balance december net loss unrealize gain availableforsale security net tax foreign currency translation adjustment unrealize loss cash flow hedge net tax comprehensive loss issuance employee stock purchase plan stock option exercise net tax benefit employee stock plan reversal defer stock compensation compensatory stock transaction assumption stock option connection acquisition purchase convertible note hedge sale warrant defer tax asset convertible note hedge repurchase common stock balance december adoption fin accounting uncertainty income taxis net income unrealize gain availableforsale security net tax foreign currency translation adjustment unrealize loss cash flow hedge net tax comprehensive income issuances employee stock purchase plan stock option exercise net tax benefit employee stock plan compensatory stock transaction repurchase common stock balance december net income unrealize loss availableforsale security net tax foreign currency translation adjustment unrealize gain cash flow hedge net tax comprehensive income issuances employee stock purchase plan stock option exercise net tax benefit employee stock plan compensatory stock transaction repurchase common stock balance december accompany note table content gilead sciences inc consolidated statement cash flow thousands year end december operating activity net income loss adjustment reconcile net income loss net cash provide operating activity depreciation amortization purchase inprocess research development stockbase compensation expense excess tax benefit stockbase compensation tax benefit employee stock plan defer income taxis noncash transaction change operate asset liability account receivable net inventory prepaid expense asset account payable income taxis payable accrue liability defer revenue minority interest net cash provide operating activity invest activity purchase marketable security proceed sale marketable security proceed maturitie marketable security acquisition net cash acquire purchase nonmarketable equity security capital expenditure net cash investing activity financing activity proceed issuance common stock proceed issuance convertible senior note net issuance cost proceed sale warrant purchase convertible note hedge repurchase common stock repayment longterm debt obligation excess tax benefit stockbase compensation net cash provide financing activity effect exchange rate change cash net change cash cash equivalent cash cash equivalent begin period cash cash equivalent end period supplemental disclosure cash flow information interest pay income taxis pay noncash investing financing activity reclassification achillion equity investment noncurrent asset marketable security achillion initial public offering accompany note table content gilead sciences inc note consolidated financial statement organization summary significant accounting policy overview gilead sciences inc gilead incorporate delaware june biopharmaceutical company discover develop commercialize innovative therapeutic area unmet medical need mission advance care patient suffer life threaten disease worldwide headquarter foster city california operations north america europe australia date focus effort bring novel therapeutic treatment life threaten disease market currently market truvada emtricitabine tenofovir disoproxil fumarate atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg viread tenofovir disoproxil fumarate emtriva emtricitabine treatment human immunodeficiency virus hiv infection hepsera adefovir dipivoxil viread treatment chronic hepatitis b infection ambisome amphotericin b liposome injection treatment severe fungal infection letairis ambrisentan treatment pulmonary arterial hypertension pah vistide cidofovir injection treatment cytomegalovirus infection flolan epoprostenol sodium treatment pulmonary hypertension f hoffmanla roche ltd hoffmanla roche inc roche market tamiflu oseltamivir phosphate treatment influenza royalty pay collaborative agreement perform manufacturing activity macugen pegaptamib sodium injection manufacturing agreement osi pharmaceuticals inc osi sell macugen treatment neovascular agerelate macular degeneration royalty pay collaborative agreement basis presentation accompany consolidated financial statement include account gilead whollyowne subsidiary joint ventures bristol myers squibb company bms primary beneficiary determine financial accounting standard board fasb interpretation revise december consolidation variable interest entity fin r record minority interest consolidate financial statement reflect bmss interest joint venture significant intercompany transaction eliminate consolidated financial statement include result company acquire date acquisition significant accounting policy estimate judgment preparation consolidate financial statement conformity united states generally accept accounting principle require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis management evaluate estimate include critical accounting policy estimate related revenue recognition allowance doubtful account prepay royalty clinical trial accrual tax provision stockbase compensation base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate revenue recognition product sale recognize revenue product sale persuasive evidence arrangement exist delivery customer occur price fix determinable collectibility reasonably assure table content gilead sciences inc note consolidated financial statementscontinue recognition revenue product sale provision government rebate customer incentive cash discount prompt payment certain distributor fee estimate future return product expire appropriate item deduct gross product sale government rebate estimate amount payable government manage medicaid program certain qualify federal state foreign government program base contractual term historical utilization rate new information change program regulation guideline impact actual rebate expectation future utilization rate program product sale channel inventory datum obtain major wholesaler accordance inventory management agreement government rebate invoice directly record accrue liability consolidate balance sheet qualified program purchase product wholesaler low contractual government price wholesaler charge difference acquisition cost low contractual government price record allowance account receivable cash discount estimate cash discount base contractual term historical utilization rate expectation future utilization rate distributor fee inventory management agreement significant wholesaler pay wholesaler fee primarily compliance certain contractually determine covenant maintenance agree inventory level distributor fee base contractually determine fix percentage sale product return provide customer general right product return permit return product damage defective receive customer case product sell unite states product expire accept product return united states expire year expiration date estimate expect return expire product base primarily ongoing analysis historical return pattern royalty revenues royalty revenue distributor sale ambisome recognize month follow month correspond sale occur royalty revenue sale product generally recognize receive generally quarter follow quarter correspond sale occur contract revenue revenue nonrefundable upfront license fee milestone payment continue obligation development collaboration obligation supply product recognize performance occur obligation complete accordance specific term gilead table content gilead sciences inc note consolidated financial statementscontinue obligation type arrangement revenue recognize obligation fulfil ratably development manufacturing period revenue associate substantive atrisk milestone recognize base achievement milestone define respective agreement advance payment receive excess amount earn classified defer revenue consolidated balance sheet contract revenue include net revenue product distribution service recognize persuasive evidence arrangement exist delivery customer occur price fix determinable collectibility reasonably assure accordance emerge issue task force eitf issue report revenue gross principal versus net agent record product distribution service revenue net supply price pay manufacturerlicensor distribution fee pay specialty pharmacy allowance product return cash discount government rebate contract revenue consolidate statement operation shipping handle cost shipping handling cost incur inventory purchase product shipment record cost good sell consolidated statement operation research development expense major component research development rd expense consist personnel cost include salary benefit stockbase compensation clinical study perform contract research organization cro material supplies license fee overhead allocation consist support facility relate cost rd activity separate main category research clinical development pharmaceutical development research cost typically consist preclinical toxicology cost clinical development cost include cost phase clinical trial pharmaceutical development cost consist expense incur connection product formulation chemical analysis charge rd cost include clinical study cost expense incur consistent statement financial accounting standard sfas accounting research development cost clinical study cost significant component rd expense clinical study perform party cro monitor level performance significant contract include extent patient enrollment activity communication cro accrue cost clinical study reflect level effort expend cro material cro contract terminable write notice generally liable actual effort expend cro certain noncancelable expense incur point termination amount pay advance relate incomplete service refund contract terminate contract include additional termination payment payable terminate contract additional termination payment record contract terminate advertising expense expense cost advertising include promotional expense incur advertising expense million million million net income loss share basic net income loss share calculate base weightedaverage number share common stock outstanding period dilute net income loss share calculate base table content gilead sciences inc note consolidated financial statementscontinue weightedaverage number share common stock outstanding dilutive security outstanding period potential dilutive share common stock result assume exercise outstanding stock option equivalent consist primarily performance share assume exercise warrant relate convertible senior note note convertible senior note note collectively note determine treasury stock method note consider instrument c security define eitf issue convertible bond issuer option settle cash conversion eitf conversion spread relate note include diluted net income loss share calculation potential dilutive share common stock result assume settlement conversion spread note determine method set forth eitf method settlement conversion spread note dilutive effect average market price common stock period exceed note note respectively average market price common stock year end december exceed conversion price note year end average market price common stock exceed conversion price note dilutive effect include table warrant relate note note dilutive effect average market price common stock period exceed warrant exercise price respectively average market price common stock year end december exceed warrant exercise price relate note stock option purchase approximately million million weightedaverage share common stock outstanding year end december respectively include computation dilute net income share option exercise price great average market price common stock period effect antidilutive net loss approximately million weightedaverage number outstanding stock option common stock equivalent include computation dilute net loss share inclusion antidilutive follow table reconciliation numerator denominator calculation basic diluted net income loss share thousands year end december numerator net income loss denominator weightedaverage share common stock outstanding calculation basic net income loss share effect dilutive security stock option equivalent conversion spread relate convertible senior note conversion spread relate convertible senior note weightedaverage share common stock outstanding calculation dilute net income loss share table content gilead sciences inc note consolidated financial statementscontinue stockbased compensation january adopt provision sfas revise sharebased payment sfas r require sharebase payment employee director include grant stock option recognize consolidated statement operation base fair value sfas r require benefit tax deduction excess recognize compensation cost report consolidated statement cash flow financing activity operating activity apply modify prospective method require compensation expense record vest nonveste stock option stockbase award begin quarter adoption sfas r addition calculate pool excess tax benefit available additional paidin capital apic accordance provision sfas r cash cash equivalent consider highly liquid investment insignificant interest rate risk original maturity month purchase date cash equivalent enter overnight repurchase agreement repos purchase security obligation resell follow day security purchase agreement resell record face value report cash cash equivalent investment policy enter repos major bank authorize dealer provide repos collateralize government security fair value fair value security sell eligible instrument investment policy include cash equivalent include commercial paper money market fund bank obligation marketable nonmarketable security determine appropriate classification marketable security consist primarily debt security include auction rate security variable rate demand obligation time purchase reevaluate designation balance sheet date marketable security consider availableforsale carry estimate fair value report cash equivalent shortterm marketable security longterm marketable security unrealize gain loss availableforsale security exclude net income loss report accumulate comprehensive income loss separate component stockholder equity interest income net include interest dividend amortization purchase premium discount realize gain loss sale security otherthantemporary decline fair value security cost security sell base specific identification method regularly review investment otherthantemporary decline fair value review include consideration cause impairment include creditworthiness security issuer number security unrealize loss position severity duration unrealize loss determine decline fair value investment accounting basis decline otherthan temporary reduce carry value security hold record loss decline result enter collaboration time time hold investment nonpublic company record nonmarketable security cost noncurrent asset amount otherthantemporary impairment regularly review investment indicator impairment investment nonmarketable security material period present concentration risk subject credit risk portfolio cash equivalent marketable security investment policy limit amount invest security duration industry group investment type table content gilead sciences inc note consolidated financial statementscontinue issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return subject credit risk account receivable relate product sale majority trade account receivable arise product sale united states europe certain country payment typically slow primarily greece italy portugal spain aggregate account receivable balance significant case slow payment practice country reflect pace governmental entity reimburse customer turn increase financial risk relate certain customer sale customer country europe tend pay relatively slowly increase continue increase average length time account receivable outstanding december account receivable greece italy portugal spain total million million day past december account receivable country total million million day past date experience significant loss respect collection account receivable believe past account receivable net allowance reflect consolidated balance sheet collectible perform credit evaluation customer financial condition generally require collateral certain raw material utilize operation obtain single supplier raw material utilize operation facility supplier key component raw material name new drug application nda file food drug administration fda product significant delay occur qualification new supplier require delivery material supplier interrupt reason unable ship product supply drug candidate clinical trial account receivable trade account receivable record net allowance wholesaler chargeback government rebate cash discount prompt payment doubtful account sale return estimate wholesaler chargeback government rebate cash discount sale return base contractual term historical trend expectation utilization rate program estimate allowance doubtful account determine base exist contractual obligation historical payment pattern customer individual customer circumstance analysis day sale outstanding customer geographic region review local economic environment potential impact government funding reimbursement practice historically amount uncollectible account receivable write insignificant consistent management expectation inventory inventory record low cost market cost determine firstin firstout basis periodically review composition inventory order identify obsolete slowmoving unsaleable item unsaleable item observe alternate use inventory record writedown net realizable value period impairment recognize prepay royalty prepay royalty capitalize cost initially equivalent present value future royalty obligation expect pay licensor expect level product sale incorporate table content gilead sciences inc note consolidated financial statementscontinue related technology review quarterly expect future sale level product indicator require writedown net recoverable value change estimate life prepay royalty amortize prepay royalty cost good sell remain life underlie patent base effective royalty rate derive forecast future product sale incorporate related technology review effective royalty rate annually prospectively adjust effective rate base significant new fact circumstance arise review prepay royalty primarily comprise emtricitabine royalty pay emory university emory hiv indication royalty pharma purchase royalty interest own emory term transaction royalty pharma pay respectively total purchase price million emory exchange elimination emtricitabine royalty emory worldwide net sale product contain emtricitabine result transaction capitalize prepaid royalty share million purchase price million december unamortized prepay royalty asset million million million million amortize cost good sell respectively property plant equipment property plant equipment state cost accumulate depreciation amortization depreciation amortization recognize straightline method repair maintenance cost expense incur estimate useful life year follow description estimate useful life building improvement laboratory manufacturing equipment office computer equipment leasehold improvement short useful life lease term office computer equipment include capitalize software capitalize software purchase internally develop software unamortize capitalize software cost million million consolidated balance sheet december respectively leasehold improvement capitalize lease equipment amortize short lease term asset useful life amortization capitalize lease equipment include depreciation expense capitalize interest construction inprogress include property plant equipment interest capitalize significant goodwill intangible asset goodwill represent excess purchase price estimate fair value net asset acquire business combination accordance sfas goodwill intangible asset sfas goodwill amortize require test annually impairment accordance sfas test goodwill impairment annual basis annual test aware event occur change circumstance indicate reduction fair value goodwill carry intangible asset definite life amortize estimate useful life review impairment fact circumstance suggest carry value asset recoverable table content gilead sciences inc note consolidated financial statementscontinue impairment longlive asset carry value longlive asset review regular basis existence fact circumstance internally externally suggest impairment specific potential indicator impairment include significant decrease fair value asset significant change extent manner asset significant physical change asset significant adverse change legal factor business climate affect value asset adverse action assessment fda regulator accumulation cost significantly excess originally expect acquire construct asset operate cash flow loss combine history operate cash flow loss projection forecast demonstrate continue loss associate income produce asset indication impairment test recoverability compare estimate undiscounted future cash flow expect result use asset asset group eventual disposition carry asset asset group estimate future cash flow asset liability group low level identifiable cash flow largely independent cash flow generate group undiscounte future cash flow carry asset asset group impairment loss measure excess carrying value asset asset group estimate fair value recognize cash flow estimate calculation base management good estimate appropriate customary assumption projection time foreign currency translation transaction contract adjustment result translate financial statement foreign subsidiary dollar exclude determination net income loss record accumulate comprehensive income loss separate component stockholder equity net foreign currency exchange transaction gain loss include interest income net consolidated statement operation net transaction gain loss total million million million respectively hedge certain foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward contract foreign currency exchange option contract general market risk contract offset correspond gain loss transaction hedge exposure credit risk contract function change interest currency exchange rate vary time limit risk counterpartie contract unable perform transact major bank monitor closely context current market condition limit risk loss enter contract provide net settlement maturity overall risk loss event counterparty default limit unrecognized gain outstanding contract ie contract positive fair value date default enter speculative foreign currency transaction hedge net investment foreign subsidiary fair value financial instrument financial instrument consist principally cash cash equivalent marketable security account receivable certain noncurrent asset foreign currency exchange forward option contract account payable longterm debt longterm obligation cash cash equivalent marketable security note foreign currency exchange contract hedge account receivable note report respective fair value balance sheet foreign currency exchange contract hedge forecast sale record fair value net relate deferred gain loss result report net balance zero remain financial instrument report consolidated balance sheet amount approximate current fair value table content gilead sciences inc note consolidated financial statementscontinue september fasb issue sfas fair value measurement sfas sfas define fair value establishe framework measure fair value expand disclosure requirement fair value measurement sfas effective fiscal year begin november financial asset liability nonfinancial asset liability recognize disclose fair value recur basis financial statement accordance fasb staff position fsp fas effective date fasb statement nonfinancial asset liability sfas effective fiscal year begin november october fasb issue fsp determine fair value financial asset market asset active fsp clarifie application sfas market active provide example illustrate key consideration determine fair value financial asset market financial asset active fsp applicable valuation auction rate security hold active market december fsp effective issuance include prior period financial statement issue january adopt provision sfas prospective basis financial asset liability sfas require determine fair value financial asset liability fair value hierarchy establish sfas describe level input measure fair value follow level input include quote price active market identical asset liability level input include observable input level input quote price similar asset liability quote price identical similar asset liability market active input observable corroborate observable market datum substantially term asset liability level input include unobservable input support little market activity significant fair value underlie asset liability level asset liability include fair value measurement determine pricing model discount cash flow methodology similar valuation technique significant management judgment estimation adoption sfa fsp effect consolidate net income year end december follow table summarize major category asset liabilitie respective fair value classification level input fair value hierarchy define sfas thousand fair value measurement december quote price active significant market significant identical observable unobservable december asset input input level level level asset cash equivalent marketable security derivative liabilitie derivative table content gilead sciences inc note consolidated financial statementscontinue follow table reconciliation marketable security measure fair value significant unobservable input level thousands year end december balance beginning period total realize loss include interest income net total unrealized loss include comprehensive income sale marketable security net purchase transfer level balance end period total loss year end december include earning attributable change unrealized loss relate asset hold reporting date report interest income net marketable security measure fair value level input substantially comprise auction rate security availableforsale investment portfolio underlie asset auction rate security comprise student loan auction rate security typically measure level input failure auction lack market activity liquidity experience begin require security measure level input fair value auction rate security determine discount cash flow model consider project cash flow issue trust underlie collateral expect yield project cash flow estimate base underlying loan principal bond outstanding payout formula weightedaverage life cash flow project consider collateral composition security relate historical project prepayment underlie student loan weightedaverage useful life year discount rate discount cash flow model base market condition comparable similar term assetbacke security fix income security adjust illiquidity discount result discount rate auction rate security reset seven day maturity date range interest rate range december auction rate security continue earn interest auction rate security measure level input record longterm marketable security consolidate balance sheet december fail auction lack market activity liquidity base assessment underlie collateral creditworthiness issuer security ability intent hold security anticipate recovery final maturity otherthantemporary impairment security december income taxis income tax provision compute liability method defer tax asset liability determine base difference financial statement tax basis asset liability enact tax rate effect year difference expect reverse significant estimate require determine provision income taxis estimate base interpretation exist tax law regulation factor favorable unfavorable effect income tax rate factor include limited interpretation exist tax law change tax law rate account stock option sharebase payment merger acquisition future level table content gilead sciences inc note consolidated financial statementscontinue rd spending change accounting standard change mix earning tax jurisdiction operate change overall level pre tax earning finalization federal state foreign income tax audits impact income tax provision result mention factor significant negative impact consolidate net income january adopt fasb interpretation accounting uncertainty income taxis fin interpretation sfas accounting income taxis sfas fin clarifie accounting uncertainty income taxis recognize enterprise financial statement accordance sfas prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return fin provide guidance derecognition classification interest penalty account interim period disclosure transition result adoption fin increase liability unrecognized tax benefit million corresponding charge opening balance accumulate deficit permit fin addition reclassify million unrecognized tax benefit shortterm income taxis payable noncurrent defer tax asset longterm income taxis payable date adoption total federal state foreign unrecognized tax benefit million record primarily longterm income taxis payable consolidated balance sheet include accrue liability relate interest million total unrecognized tax benefit million recognize reduce effective tax rate period recognition permit provision fin continue classify interest penalty relate unrecognized tax benefit income tax provision consolidated statement operation recent accounting pronouncement june fasb ratify eitf issue determine instrument embed feature index entitys stock eitf eitf provide guidance determine certain instrument embed feature consider indexed stock include instrument similar note convertible note hedge warrant purchase stock forward contract enter accelerate share repurchase transaction february complete june forward contract enter accelerate share repurchase transaction october eitf require company use twostep approach evaluate instrument contingent exercise provision settlement provision determine instrument consider index stock exempt application sfas accounting derivative instrument hedge activity eitf effective fiscal year begin december outstanding instrument date adoption require retrospective application accounting cumulative effect adjustment retain earning adoption expect adoption eitf material impact consolidate financial position result operation fasb issue fsp apb accounting convertible debt instrument settle cash conversion include partial cash settlement fsp apb fsp apb address instrument commonly refer instrument c eitf require issuer settle principal cash conversion spread cash net share issuer option fsp apb require issuer instrument account liability equity component separately bifurcate conversion option debt instrument classify conversion option equity accrete result discount debt additional interest expense expect life debt fsp apb effective fiscal year begin december interim period fiscal year require retrospective application period present early application permit expect adoption fsp apb material impact consolidate financial position table content gilead sciences inc note consolidated financial statementscontinue result operation base requirement fsp apb estimate fsp apb effective current comparative period report additional interest expense relate convertible senior note approximately million million million respectively december fasb issue sfas noncontrolle interest consolidate financial statement amendment accounting research bulletin consolidated financial statement sfas sfas establish accounting reporting standard ownership interest subsidiary hold party parent consolidate net income loss attributable parent noncontrolle interest change parent ownership interest valuation retain noncontrolle equity investment subsidiary deconsolidate sfas establish additional reporting requirement identify distinguish ownership interest parent interest noncontrolle owner sfas effective interim period fiscal year begin december adopt sfas plan reclassify noncontrolle interest minority interest consolidate balance sheet liability stockholder equity present noncontrolle interest minority interest consolidate statement operation net income attributable noncontrolle interest component total consolidated net income loss december fasb issue sfas revise business combination sfas r sfas r establish principle requirement recognize measure asset acquire liability assume noncontrolle interest acquiree business combination sfas r provide guidance recognize measure goodwill acquire business combination requires purchase inprocess research development iprd capitalize fair value intangible asset time acquisition require acquisitionrelate expense restructure cost recognize separately business combination expand definition constitute business require acquirer disclose information user need evaluate understand financial effect business combination sfas r effective prospective basis impact business combination transaction acquisition date occur december depend nature magnitude future business combination transaction sfas r material impact consolidate financial position andor result operation derivative financial instrument derivative recognize asset liability measure fair value base quote market price enter foreign currency forward contract hedge change fair value certain monetary asset liability denominate nonfunctional currency record change fair value instrument interest income net derivative instrument designate hedge sfas nos accounting derivative instrument hedge activity collectively refer sfas enter foreign currency forward option contract maturity month hedge percentage future cash flow relate forecasted product sale certain foreign currency derivative instrument employ eliminate minimize certain foreign currency exposure confidently identify quantify hedge relate forecasted foreign currency denominate product sale designate document inception respective hedge designate cash flow hedge sfas evaluate effectiveness quarterly inception hedge relationship quarterly basis perform regression analysis take change cash flow underlie contract regress change cash flow hedge instrument exclude time value assess effectiveness hedge relationship assess hedge effectiveness retrospective basis dollar offset approach table content gilead sciences inc note consolidated financial statementscontinue monthly exclude time value effectiveness testing recognize change time value hedge interest income net exclude gain loss million million million assessment hedge effectiveness respectively effective component hedge record accumulate comprehensive income loss unrealize gain loss hedge instrument note hedge forecast transaction occur hedge dedesignate unrealized gain loss reclassify product sale time substantially value report accumulate comprehensive income december reclassify product sale month december net unrealized gain loss million million respectively open foreign currency exchange contract net loss cash flow hedge record product sale decrease product sale million million million respectively residual change fair value hedge instrument include result cancellation dedesignation hedge contract ineffectiveness recognize immediately interest income net impact hedge ineffectiveness significant consolidated statement operation notional amount foreign currency exchange forward option contract outstanding billion december billion december hedge asset liability fair value million million december respectively acquisition navita asset llc execute asset purchase agreement navita asset llc navita acquire asset relate cicletanine business acquire exclusive right regulatory data filing development cicletanine monotherapy pah indication united states plan evaluate cicletanine potential treatment pah aggregate purchase price acquisition million consist primarily cash pay addition navita entitle potential additional purchase consideration include payment contingent future achievement certain development regulatory milestone amount record related contingency resolve purchase price allocate iprd represent purchase iprd program cicletanine reach technological feasibility alternative future use acquisition date expense acquisition consolidated statement operation nycome limited september complete acquisition nycome limited nycome whollyowne irish subsidiary germanybase pharmaceutical company nycome gmbh nycome facility locate cork ireland conduct manufacturing tablete operation nycome gmbh transfer certain manufacturing operation dublin ireland area site facility utilize site primarily solid dose tablet manufacturing exist future product product packaging nycome acquisition account business combination accordance sfas business combination sfas result operation nycome completion acquisition september include consolidated statement operation table content gilead sciences inc note consolidated financial statementscontinue aggregate purchase price nycomed common stock million consist cash pay closing million estimate direct transaction cost million employeerelate severance cost million employeerelate severance cost capitalize purchase price establish workforce reduction plan acquisition transaction accordance eitf issue recognition liability connection purchase business combination eitf cost fully pay purchase price allocate primarily property plant equipment million remain balance allocate net work capital september connection transfer certain manufacturing operation dublin ireland area site cork facility finalize personnel plan respect dublin employee meet criterion recognize expense onetime termination benefit sfas accounting cost associate exit disposal activity fourth quarter estimate termination benefit total approximately million myogen inc november complete acquisition outstanding share common stock myogen cash tender offer term agreement plan merger enter october myogen publiclyheld biopharmaceutical company base westminster colorado focus discovery development commercialization small molecule therapeutic treatment cardiovascular disorder myogen product candidate late stage clinical development ambrisentan treatment patient pah darusentan treatment patient resistant hypertension acquisition provide opportunity expand cardiovascular therapeutic area myogen acquisition account business combination accordance sfas result operation myogen november include consolidated statement operation aggregate purchase price myogen common stock billion consist cash pay prior closing billion fair value vest stock option assume million direct transaction cost million consist primarily investment banking fee employee relate severance cost million reduction income taxis payable million result primarily exercise stock option assume myogen vest acquisition date reduction income taxis payable result decrease aggregate purchase price employeerelate severance cost capitalize purchase price establish workforce reduction plan acquisition transaction accordance eitf cost fully pay accordance merger agreement enter myogen conversion value stock option assume determined base exercise price option purchase share common stock myogen average closing price common stock consecutive trading day immediately precede include tender offer acceptance date november share estimate fair value stock option assume determined average price share approximate price resulted average closing price common stock trading day trading day acceptance date accordance eitf issue determination measurement date market price acquirer security issue purchase business combination fair value stock option assume calculate blackschole valuation model follow assumption expect term range year riskfree interest rate range expect volatility range dividend yield fair value convert gilead stock option exceed fair value myogen stock option immediately prior exchange table content gilead sciences inc note consolidated financial statementscontinue approximately million million convert share subject outstanding myogen stock option fully vest acquisition date estimate fair value vest option million include purchase price estimate fair value unvested option million include purchase price recognize stockbase compensation expense remain future vest period option follow table summarize purchase price allocation november thousands cash cash equivalent shortterm marketable security account receivable net prepaid expense asset account payable defer revenue liability net tangible asset defer tax asset purchase inprocess research development goodwill total purchase price million defer revenue reflect fair value defer revenue legal performance obligation accordance eitf issue accounting business combination defer revenue acquiree million defer tax asset primarily related federal net operating loss tax credit carryforward certain state amortization conclude base standard set forth sfas likely realize benefit defer tax asset elect treat myogen acquisition asset acquisition california state tax purpose purchase iprd goodwill result acquisition deductible california state income tax purpose amount deductible federal income tax purpose estimate fair value purchase iprd billion determined management purchase iprd represent myogen incomplete rd program reach technological feasibility alternative future use acquisition date expense acquisition consolidated statement operation summary program acquisition date update subsequent change status development follow table content gilead sciences inc note consolidated financial statementscontinue estimate acquisition date fair value program description status development millions ambrisentan orally active nonsulfonamide phase clinical trial complete prior acquisition date file propanoic acidclass endothelin receptor nda fda december june fda antagonist era treatment pah approve letairis treatment pah united states additionally march european medicine agency emea validate marketing authorization application ambrisentan treatment pah file collaboration partner glaxosmithkline inc gsk april european commission grant gsk marketing authorization ambrisentan treatment pah market volibris gsk darusentan orally active etaselective era phase clinical development acquisition date date treatment resistant hypertension filing estimate fair value purchase iprd determine income approach discount expect future cash flow present value estimate fair value purchase iprd present value discount rate base estimate internal rate return myogen operation comparable estimate weightedaverage cost capital company myogen profile represent rate market participant use value purchase iprd compensate differ phase development ambrisentan darusentan probabilityadjuste estimation expect future cash flow associate program determine time present value expect future cash flow discount rate project cash flow ambrisentan darusentan program base key assumption estimate revenue operate profit relate program consider stage development time resource need complete development approval relate product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop drug compound obtain fda regulatory approval risk relate viability potential alternative treatment future target market remain effort complete darusentan iprd program consist primarily clinical trial cost length success extremely difficult predict obtain necessary regulatory approval numerous risk uncertainty exist prevent completion development include possibility unfavorable result clinical trial risk fail obtain fda regulatory body approval feedback regulatory authority result clinical trial require modification delay later stage clinical trial additional trial perform certain darusentan treatment resistant hypertension approve united states country outside united states marketing approval significant limitation use future discussion regulatory agency determine datum need timeline review differ materially current projection darusentan successfully commercialize result strategic decision discontinue development darusentan example believe commercialization difficult relative opportunity pipeline program complete timely basis prospect future revenue growth adversely impact assurance give underlie assumption forecast cash flow timely table content gilead sciences inc note consolidated financial statementscontinue successful completion project materialize estimate reason actual result vary significantly estimate result excess purchase price fair value amount assign asset acquire liability assume million represent goodwill result myogen acquisition record goodwill noncurrent asset consolidated balance sheet acquisition date accordance sfas goodwill test impairment annual basis annual test aware event occur change circumstance indicate reduction fair value goodwill carry raylo chemicals inc november complete acquisition outstanding share common stock raylo chemicals inc raylo whollyowne subsidiary germanybase specialty chemical company degussa ag locate edmonton canada raylos operations encompass custom manufacture active pharmaceutical ingredient advanced intermediate pharmaceutical biopharmaceutical industry utilize raylo site process research scaleup clinical development candidate manufacture active pharmaceutical ingredient investigational commercial product chemical development activity improve exist commercial manufacturing process raylo acquisition account business combination accordance sfas result operation raylo november include consolidated statement operation aggregate purchase price raylo common stock million consist cash pay prior closing million direct transaction cost million employeerelate severance cost million employeerelate severance cost capitalize purchase price establish workforce reduction plan acquisition transaction accordance eitf cost fully pay follow table summarize purchase price allocation november thousands net tangible asset gmp qualification intangible asset goodwill total purchase price million net tangible asset include million cash million property plant equipment million tangible asset assume liability million estimate fair value million associate good manufacturing practice gmp qualification raylos facilities determine management value record intangible asset amortize straightline basis year estimate useful life asset determine management base time derive benefit substantial upgrade revision acquire manufacturing practice december accumulate amortization asset million million respectively amortization expense recognize million million million respectively estimate amortization expense recognize approximately million asset expect fully amortize november excess purchase price fair value amount assign asset acquire liability assume million represent goodwill result raylo acquisition record table content gilead sciences inc note consolidated financial statementscontinue goodwill noncurrent asset consolidated balance sheet acquisition date elect treat raylo acquisition asset acquisition federal california state tax purpose goodwill result acquisition deductible federal california state income tax purpose prior acquisition raylo longstanding contract manufacturer determine accordance eitf issue accounting preexisting relationship party business combination settlement preexist relationship business combination value need assign preexist relationship purchase price allocation summarize raylos assets acquisition date include million trade receivables eliminate consolidated balance sheet completion acquisition corus pharma inc august complete acquisition corus privatelyheld biopharmaceutical company base seattle washington corus development stage company focus development commercialization novel drug respiratory infectious disease corus lead product candidate late stage clinical trial early stage product candidate acquisition provide opportunity expand respiratory therapeutic area augment pipeline corus acquisition account acquisition asset business combination accordance criterion outline eitf issue determine nonmonetary transaction involve receipt productive asset business sfas corus consider development stage company commence plan principal operation additionally lack necessary element business include complete product ability access customer result operation coru august include consolidated statement operation april purchase million coruss series c prefer stock represent approximately coruss voting equity interest time conjunction purchase series c prefer stock enter agreement plan merger option acquire merger remain outstanding share corus july announce agree exercise option concurrently enter agreement novartis vaccine diagnostics inc novartis novartis agree dismiss litigation corus payment novartis claim novartis directly implicate coruss right develop commercialize product settle novartis deem appropriate allow completion acquisition ensure claim novartis impede ability develop commercialize coruss product candidate settlement result ongoing trial time settlement uncertain sustained period follow close legal appeal potential proceeding completion acquisition include investment coruss series c prefer stock payment novartis acquisition purchase price aggregate purchase price acquire share million consist cash pay prior closing million fair value vest stock option assume million direct transaction cost million employeerelate severance cost million addition holdback million payable corus stockholder year closing merger extent utilize pay claim year assess probable pay holdback record accrue liability consolidate balance sheet acquisition date pay holdback million august employeerelate severance cost capitalize purchase price establish workforce reduction plan acquisition transaction cost fully pay table content gilead sciences inc note consolidated financial statementscontinue follow table summarize purchase price allocation august thousand net tangible asset assemble workforce net defer tax asset purchase inprocess research development total purchase price million net tangible asset include million cash million marketable security million tangible asset assume liability million million value assign assemble workforce amortize year estimate useful life asset million net defer tax asset primarily related federal net operating loss tax credit carryforward certain state amortization conclude base standard set forth sfas likely realize benefit defer tax asset elect treat corus acquisition asset acquisition california state tax purpose purchase iprd result acquisition deductible california state income tax purpose deductible federal income tax purpose estimate fair value purchase iprd assemble workforce determine management estimate fair value purchase iprd great purchase price pay allocate purchase iprd consist net remain allocate purchase price net tangible asset assemble workforce net defer tax asset purchase iprd represent coruss incomplete rd program reach technological feasibility alternative future use acquisition date expense acquisition consolidated statement operation summary program acquisition date update subsequent change status development follow estimate acquisition date fair value program description status development million aztreonam inhalation aztreonam formulation phase clinical trial acquisition date file nda solution inhalation fda november september receive complete treatment cystic gramnegative bacteria response letter fda inform fda approve fibrosis cf cause lung infection patient nda aztreonam inhalation solution treatment cf cf current form request conduct additional phase clinical study november file request formal dispute resolution fda february response appeal fda notify reiterate position need conduct clinical study aztreonam inhalation solution resubmit nda submit marketing authorization application european union receive notice acceptance priority review health canada approval canada await response respective regulatory body table content gilead sciences inc note consolidated financial statementscontinue estimate fair value purchase iprd determine income approach discount expect future cash flow present value estimate fair value purchase iprd present value discount rate base estimate internal rate return coruss operation comparable estimate weightedaverage cost capital company coruss profile represent rate market participant use value purchase iprd project cash flow aztreonam inhalation solution program base key assumption estimate revenue operate profit relate program consider stage development time resource need complete development approval relate product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop drug compound obtain fda regulatory approval risk relate viability potential alternative treatment future target market coruss early stage candidate include valuation purchase iprd early stage project identifiable revenue expense associate remain effort complete coruss iprd program consist primarily clinical trial cost length success extremely difficult predict numerous risk uncertainty exist prevent completion development include possibility unfavorable result clinical trial risk fail obtain fda regulatory body approval certain aztreonam inhalation solution treatment cf approve united states country outside united states marketing approval significant limitation use aztreonam inhalation solution treatment cf successfully commercialize result strategic decision discontinue development aztreonam inhalation solution treatment cf example believe commercialization difficult relative opportunity pipeline program complete timely basis prospect future revenue growth adversely impact assurance give underlie assumption forecast cash flow timely successful completion project materialize estimate reason actual result vary significantly estimate result acquisition real estate october sign purchase sale agreement purchase office building approximately acre land locate foster city california aggregate purchase price approximately million initial refundable deposit million escrow october include current asset december january remain balance million pay escrow closing transaction closing purchase sale agreement amend allow holdback escrow million purchase price release depend outcome certain requirement mutually agree close asset disposal march receive local city approval proceed demolition building foster city california begin construction new facility include charge associate writeoff building equal aggregate net book value million sga expense table content gilead sciences inc note consolidated financial statementscontinue availableforsale security follow summary availableforsale security record cash equivalent marketable security consolidate balance sheet estimate fair value availableforsale security generally base price obtain commercial pricing service thousand gross gross amortize unrealize unrealized estimate cost gain loss fair value december debt security treasury security government sponsor entity debt security corporate debt security assetbacke security municipal debt security debt security total debt security equity security total december debt security treasury security government sponsor entity debt security corporate debt security assetbacke security municipal debt security debt security total debt security equity security total december debt security consist primarily money market fund auction rate security follow table present classification availableforsale security consolidate balance sheet thousand december cash cash equivalent shortterm marketable security longterm marketable security total december portfolio availableforsale debt security comprise billion security contractual maturity year billion security contractual table content gilead sciences inc note consolidated financial statementscontinue maturity great year year million security contractual maturity great year year million security contractual maturity great year security contractual maturity great year comprise asset back security include mortgagebacke security auction rate security follow table present certain information relate sale marketable security thousand year end december gross realize gain sale gross realize loss sale december follow availableforsale debt security continuous unrealized loss position deem otherthantemporarily impair thousand month month great gross gross unrealize estimate unrealized estimate loss fair value loss fair value december government sponsor entity debt security corporate debt security assetbacke security municipal debt security debt security total december treasury security government sponsor entity debt security corporate debt security assetbacke security municipal debt security total december gross unrealized loss primarily cause increase yieldtomaturity underlie security approximately total number investment unrealize loss position case auction rate security gross unrealized loss cause high discount rate valuation security compare coupon rate security significant fact circumstance arise indicate deterioration creditworthiness issuer security base review security include assessment duration severity relate unrealized loss ability intent hold investment maturity otherthan temporary impairment security december result review investment otherthantemporary impairment record total charge million interest income net writedown cost basis investment common stock achillion pharmaceuticals inc achillion note assetbacked commercial paper abcp structure investment vehicle million million respectively december table content gilead sciences inc note consolidated financial statementscontinue record total charge million interest income net writedown cost basis investment common stock achillion assetbacke commercial paper abcp structure investment vehicle million million respectively otherthantemporary impairment achillion base quote market price achillion common stock september december compare cost basis assessment base primarily observation quote market value investment carrying value consecutive quarter otherthantemporary impairment abcp base market factor include estimate fair value underlie collateral abcp december investment common stock achillion abcp million million respectively record longterm marketable security shortterm marketable security respectively consolidated balance sheet inventory inventory summarize follow thousand december raw material work process finish good total inventory december joint venture form gilead bms note include consolidated financial statement hold million million inventory respectively efavirenz active pharmaceutical ingredient purchase bms bmss estimate net selling price sustiva establish gilead access program pursuant truvada viread available substantially reduce price country develop world base regular evaluation forecast sale pricing inventory shelf life conclude fully recover carrying value associate inventory truvada viread gilead access program result record charge million cost good sell write inventory estimate net realizable value table content gilead sciences inc note consolidated financial statementscontinue property plant equipment property plant equipment summarize follow thousand december property plant equipment net building improvement include leasehold improvement laboratory manufacturing equipment office computer equipment capitalize lease equipment construction progress subtotal accumulate depreciation amortization include relate capitalize lease equipment respectively subtotal land total collaborative arrangement result enter strategic collaboration time time hold investment nonpublic company review interest investee company consolidation andor appropriate disclosure provision fin r december determine certain investee company variable interest entity respect joint venture bms primary beneficiary consolidate investee bristolmyers squibb company north america december enter collaboration bms united states develop commercialize single tablet regimen contain truvada bmss sustiva collaboration structure joint venture operate limited liability company consolidate name bristolmyers squibb gilead sciences llc ownership interest joint venture share product revenue cost reflect respective economic interest bms base proportion net selling price atripla attributable sustiva truvada net selling price truvada change time relative net selling price sustiva bms respective economic interest joint venture vary annually share marketing sale effort bms party obligate provide equivalent sale force effort minimum number year responsible accounting financial reporting tax reporting product distribution joint venture party provide respective bulk active pharmaceutical ingredient joint venture approximate market value july joint venture receive approval fda sell atripla united states september bms amend joint venture collaboration agreement allow joint venture sell atripla canada october joint venture receive approval health canada sell atripla canada december joint venture hold efavirenz active pharmaceutical ingredient purchase bms table content gilead sciences inc note consolidated financial statementscontinue bmss estimate net selling price sustiva market amount include inventory consolidate balance sheet december total asset hold joint venture billion million respectively consist cash cash equivalent account receivable include intercompany receivables gilead inventory prepaid asset december total liability hold joint venture million million respectively consist account payable include intercompany payable gilead accrue expense primary beneficiary joint venture legal structure joint venture limit recourse creditor general credit asset europe december gilead sciences limited gsl whollyowne subsidiary ireland bms enter collaboration arrangement commercialize distribute atripla european union norway iceland switzerland liechtenstein european territory party form limited liability company consolidate manufacture atripla distribution europe efavirenz purchase bms bmss estimate net selling price efavirenz european territory responsible product distribution inventory management warehouse local subsidiary primary responsibility order fulfillment collection receivables customer relation handle sale return territory copromote atripla bms responsible accounting financial reporting tax reporting collaboration december european commission approve atripla sale european union december efavirenz purchase bms bmss estimate net selling price efavirenz european territory include inventory consolidate balance sheet party form bristolmyers squibb gilead sciences limit limited liability company hold marketing authorization atripla europe primary responsibility regulatory activity share marketing sale effort bm major market country party agree provide equivalent sale force effort revenue cost sharing base relative ratio truvada sustivas respective net selling price pari gmbh result acquisition corus august assume right february development agreement corus pari gmbh pari development aztreonam inhalation solution development inhalation delivery device drug candidate term agreement obligate pay pari service render subject achievement specific milestone obligate pay certain milestone payment pari addition royalty payment base net sale aztreonam inhalation solution approve commercialization agreement provide right reduce royalty rate payable pari november pay pari million reduce royalty rate agreement aztreonam inhalation solution approve commercialization record payment rd expense consolidate statement operation april pursuant february development agreement enter commercialization agreement pari provide supply manufacture inhalation delivery device accessory use aztreonam inhalation solution term agreement obligate pay royalty future net sale product pursuant development agreement table content gilead sciences inc note consolidated financial statementscontinue lg life sciences ltd november enter license agreement lg life sciences ltd lgls develop commercialize certain caspase inhibitor treatment fibrotic disease agreement grant commercialization right lglss caspase inhibitor include lb gs term agreement license worldwide exception korea china india lgls retain right lgls retain right develop commercialize caspase inhibitor ophthalmic topical use worldwide accordance term agreement pay million upfront license fee record rd expense consolidate statement operation future alternative use technology agreement obligate fund collaborative research program year identify potential caspase inhibitor drug candidate addition obligate additional milestone payment million achievement certain development regulatory commercial objective obligate pay royalty future net sale product develop approve relation collaboration parion sciences inc august enter research collaboration license agreement parion sciences inc parion research develop commercialize certain epithelial sodium channel inhibitor treatment pulmonary disease agreement grant worldwide commercialization right p gs epithelial sodium channel enac inhibitor discover parion treatment pulmonary disease include cf chronic obstructive pulmonary disease noncf bronchiectasis accordance term agreement pay million upfront license fee record rd expense consolidate statement operation future alternative use technology million investment parion form convertible debt record noncurrent asset consolidate balance sheet collaboration agreement lead development commercialization activity provide funding time equivalent employee certain research activity addition obligate additional payment achievement certain milestone pay royalty future net sale product develop approve relation collaboration roche september enter development license agreement agreement roche develop commercialize therapy treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codevelope roche agreement roche exclusive right manufacture sell tamiflu worldwide subject obligation pay percentage net revenue roche generate tamiflu sale turn subject reduction certain define manufacturing cost november enter amendment supplement agreement roche amend agreement provide formation joint manufacturing committee review roche manufacturing capacity tamiflu global plan manufacture tamiflu commercial committee evaluate commercial plan strategy tamiflu united states joint supervisory committee evaluate roche overall commercial plan tamiflu global basis case consist representative roche amend agreement option provide specialized sale force supplement roche marketing effort united states tamiflu royalty payable net sale tamiflu sell roche remain amend agreement follow million worldwide net sale give calendar year b million worldwide net sale calendar year c table content gilead sciences inc note consolidated financial statementscontinue worldwide net sale excess million calendar year amend agreement revise provision agreement relate calculation royalty payment give calendar quarter roche pay royalty base actual royalty rate applicable quarter addition amend agreement royalty payable roche long subject cost good sell adjustment provide agreement record total million million million tamiflu royalty respectively japan tobacco inc march japan tobacco grant exclusive right develop commercialize elvitegravir novel hiv integrase inhibitor know gs country world exclude japan japan tobacco retain right term agreement incur upfront license fee million include rd expense future alternative use technology march record million rd expense relate milestone incur result dose patient phase clinical study july record million rd expense relate milestone pay related dose patient phase clinical study obligate additional payment achievement milestone pay royalty future product sale arise collaboration achillion pharmaceuticals inc november achillion grant worldwide right research development commercialization certain small molecule hepatitis c virus hcv replication inhibitor involve hcv protease treatment hepatitis c collaboration achillion obligate continue development inhibitor compound accord mutually agree development plan completion proof concept clinical study hcv infected patient cost incur achieve proof concept shared equally achillion follow proof concept study obligate assume responsibility incur cost associate development commercialization compound warrant development achillion option participate commercialization effort future product arise collaboration conjunction signing collaboration pay million upfront license fee record rd expense future alternative use license technology additionally invest million achillion convertible prefer stock agree payment achillion achievement certain milestone outline agreement pay royalty future net sale product arise collaboration october achillion complete initial public offering convertible preferred stock convert share achillion common stock record writedown million million respectively review otherthantemporary impairment quote market price achillion common stock cost basis consecutive quarter glaxosmithkline inc april grant gsk right commercialize hepsera oral antiviral treatment chronic hepatitis b asia latin america certain territory agreement retain right hepsera united states canada europe australia new zealand turkey gsk receive exclusive right develop hepsera solely treatment chronic hepatitis b territory significant include china japan south korea taiwan gsk responsibility development commercialization hepsera territory term agreement receive table content gilead sciences inc note consolidated financial statementscontinue upfront license payment million receive aggregate million milestone payment relate commercial approval hepsera country receive aggregate million milestone payment gsk achievement gsk consecutive quarter hepsera gross sale exceed million achievement certain drug status china upfront license fee milestone payment record defer revenue total million million million amortize contract revenue respectively million balance defer revenue december expect amortize contract revenue period supply hepsera gsk term agreement gsk require pay royalty net sale gsk generate sale hepsera epivir hbvzeffix gsk hepatitis product gsk territory record million million million royalty revenue respectively result acquisition myogen november assume right march license distribution supply agreement myogen gsk term license agreement gsk receive exclusive sublicense right ambrisentan certain hypertensive condition territory outside united states receive upfront payment million subject achievement specific milestone eligible receive total additional milestone payment million addition receive step royalty base net sale ambrisentan gsk territory gsk option negotiate exclusive sublicense additional therapeutic use ambrisentan gsk territory term license agreement continue conduct bear expense clinical development activity believe required obtain maintain regulatory approval ambrisentan united states canada european economic area party conduct additional development activity territory expense party agree jointly develop ambrisentan new indication license field party pay share external cost associate joint development receive milestone payment million gsk validation emea marketing authorization application ambrisentan treatment pah receive million milestone payment relate european commission marketing authorization approval ambrisentan treatment pah market volibris gsk milestone upfront license payment record defer revenue amortize contract revenue remain period performance obligation agreement approximately seven year amortize million million million contract revenue respectively longterm obligation convertible senior note april issue million principal convertible senior note note million principal convertible senior note note collectively note private placement pursuant rule securities act amend note note issue par bear interest rate respectively debt issuance cost million connection issuance note record noncurrent asset amortize interest expense straightline basis contractual term note aggregate principal note sell reflect exercise initial purchaser option purchase additional note cover allotment note convertible common stock base initial conversion rate share principal note represent initial conversion price approximately share note convertible common stock base initial conversion rate share principal note represent initial conversion price approximately share note convert subject adjustment follow circumstance calendar quarter beginning table content gilead sciences inc note consolidated financial statementscontinue september closing price common stock trading day consecutive trading day period previous quarter applicable conversion price share specified distribution holder common stock specify corporate transaction occur month prior maturity applicable note conversion holder receive cash equal less principal note ii conversion value note conversion value exceed deliver option cash common stock combination cash common stock conversion value excess note convert connection change control require provide premium form increase conversion rate subject state maximum addition event change control holder require purchase portion note purchase price equal principal note plus accrue unpaid interest thereon december fair value note note approximately million million respectively base quote market value concurrent issuance note purchase convertible note hedge private transaction cost million cover subject customary antidilution adjustment million share common stock strike price correspond initial conversion price note market value share common stock time conversion note strike price applicable convertible note hedge entitle receive counterpartie transaction cash share common stock combination cash common stock option excess market price common stock strike price convertible note hedge convertible note hedge terminate maturity relate note relate note remain outstanding conversion sell warrant acquire million share common stock subject customary antidilution adjustment private transaction receive net proceed million market value common stock time exercise applicable warrant exceed respective strike price require net settle cash share common stock option respective counterpartie value warrant excess warrant strike price maximum number share common stock issue choose net share settle warrant million share underlie share reserve potential future issuance warrant strike price share warrant expire share warrant expire exercisable respective expiration date take convertible note hedge warrant intend reduce potential dilution future conversion note effectively increase initial conversion price share note share note net cost million convertible note hedge warrant transaction record stockholder equity choice settle convertible note hedge warrant cash share stock contract meet applicable criterion equity classification outline eitf issue account derivative financial instrument index potentially settle company stock eitf cost convertible note hedge net proceed sale warrant classify stockholder equity addition contract classify stockholder equity index common stock account derivative sfas record defer tax asset million apic effect future tax benefit relate convertible note hedge accordance sfas eitf issue income tax consequence issue convertible debt beneficial conversion feature contemporaneously close sale note portion net proceed note issuance proceed warrant transaction repurchase million share common stock million stock repurchase program table content gilead sciences inc note consolidated financial statementscontinue term note agreement require comply certain covenant december compliance covenant credit facility december enter agreement syndicate bank year million senior credit facility million facility consist uncollateralized million term loan enter gilead biopharmaceutics ireland corporation gbic whollyowne irish subsidiary uncollateralize million revolve credit facility enter parent company gilead sciences inc proceed term loan gbic december facilitate cash dividend distribution million parent company repatriation qualified foreign earning provision american job creation act ajca year end december repay million represent remain amount term loan time term loan terminate term revolve credit facility enter december interest accrue payable rate libor plus tiere contractual rate basis point payable quarterly arrear parent company prepay outstanding borrowing accrue interest prepay principal time penalty premium outstanding interest principal december payable demand capacity revolve credit facility increase maximum million term loan repay ability irrevocably cancel unutilized portion revolve credit facility proceed obtain revolve credit facility expect work capital capital expenditure general corporate purpose include issuance letter credit million whollyowne subsidiary guarantor december enter amend restate credit agreement supersede exist revolve credit agreement syndicate bank increase credit facility billion amend restate credit agreement include subfacility swingline loan letter credit enter gbic parent company term amend restate credit agreement borrow initially aggregate billion revolving credit loan loan amend restate credit agreement bear interest libor plus margin range basis point basis point ii base rate define amend restate credit agreement prepay outstanding borrowing time penalty premium outstanding interest principal payable december connection amend restate credit agreement parent company enter agreement guarantee obligation gbic amend restate credit agreement expect use proceed loan amend restate credit agreement work capital requirement general corporate purpose december million letter credit outstanding amend restate credit agreement require comply certain covenant amend restate credit agreement december compliance covenant commitment contingency lease arrangement enter longterm noncancelable operating lease equipment facility lease facility foster city san dimas california durham north carolina boulder westminster colorado seattle washington dublin area ireland london area united kingdom table content gilead sciences inc note consolidated financial statementscontinue operating lease sale marketing administrative facilities europe canada australia lease expire date lease ireland united kingdom year respectively rent subject increase fifth anniversary respective commencement date facility lease option renew equipment lease include corporate aircraft vary term renewal option expiration lease term lease expense operating lease total approximately million million million aggregate noncancelable future minimum rental payment operating lease year end december follow thousand legal proceeding united states district court northern district california execute order dismiss entirety prejudice fourth consolidated amend complaint associate purport class action lawsuit chief executive officer chief operating officer executive vice president operation executive vice president research development chief scientific officer senior vice president manufacture senior vice president research allege defendant violate federal security law specifically section b securities exchange act amend rule b promulgate sec make certain allege false misleading statement august united states court appeals ninth circuit reverse district court decision remand case district court february file petition writ certiorari supreme court united states request court review judgment court appeal supreme court review petition case continue district court february file motion dismiss fourth consolidated amend complaint possible predict outcome case amount accrue relate outcome case november receive subpoena united states attorney office san francisco request document market medical education program truvada viread emtriva cooperate continue cooperate relate governmental inquiry possible predict outcome inquiry amount accrue relate outcome inquiry party legal action arise ordinary course business believe legal action material adverse impact consolidate business financial position result operation commitment august result review term exist corporate aircraft lease consideration alternative available expiration enter agreement table content gilead sciences inc note consolidated financial statementscontinue purchase aircraft construct delivery aggregate purchase price purchase agreement million december deposit total million record noncurrent asset consolidate balance sheet future deposit term purchase agreement follow million million million million million option terminate purchase agreement subject maximum payment fully equip price aircraft normal course business enter firm purchase commitment relate active pharmaceutical ingredient certain inventory relate item december commitment year million million million million million amount relate active pharmaceutical ingredient represent minimum purchase requirement actual payment purchase relate active pharmaceutical ingredient billion million million year end december respectively stockholders equity stock repurchase programs march board directors board authorize program repurchase common stock billion year period open market private block transaction pursuant rule b plan privately negotiate purchase mean include accelerated stock repurchase transaction similar arrangement april repurchase retire share common stock share aggregate purchase price million june repurchase retire aggregate share common stock average purchase price share aggregate purchase price million stock repurchase program expire march october board authorize new program repurchase common stock billion open market private block transaction pursuant rule b plan privately negotiate purchase mean include accelerated stock repurchase transaction similar arrangement repurchase plan expire december repurchase retire share common stock share aggregate million billion stock repurchase program february enter accelerate share repurchase agreement financial institution repurchase million common stock accelerate basis term accelerate share repurchase agreement pay million financial institution settle initial purchase transaction receive share common stock price share june maturity agreement accordance share delivery provision agreement receive additional share common stock base average daily volume weight average price common stock specify period predetermined discount share result final purchase price common stock accelerate share repurchase share accordance eitf issue accounting accelerate share repurchase program account accelerate share repurchase separate transaction share common stock acquire treasury stock transaction record transaction date b forward contract index common stock account share receive repurchase common stock retire share immediately net income share purpose additional table content gilead sciences inc note consolidated financial statementscontinue share receive maturity contract june record stockholder equity determine forward contract index common stock meet applicable criterion equity classification accordance eitf contract account derivative sfas october enter accelerate share repurchase agreement financial institution repurchase million common stock accelerate basis term accelerate share repurchase agreement pay million financial institution settle initial purchase transaction receive share common stock price share april subject extension certain circumstance maximum minimum share delivery provision agreement receive additional share financial institution depend average daily volume weightedaverage price common stock specify period predetermined discount share make initial payment million obligate deliver cash share financial institution certain limited circumstance case method delivery cash share common stock discretion accounting accelerate share repurchase consistent previous accelerated share repurchase addition common stock repurchase accelerated share repurchase transaction repurchase retire share common stock average purchase price share aggregate purchase price million open market transaction december remain authorize stock repurchase billion stock repurchase program expire december million use par value method accounting stock repurchase par value method common stock charge par value share involve excess cost share acquire par value allocate apic base estimate average sale price issue share excess amount charge retain earning result stock repurchase reduce common stock apic aggregate million charge million retain earning result stock repurchase reduce common stock apic aggregate million charge billion retain earning prefer stock share authorize preferred stock issuable series board authorize determine designation power preference right series designate share series junior participate prefer stock potential issuance november right agreement bny mellon investor service llc know chasemellon shareholder services llc amend right plan prefer stock outstanding december right plan right plan provide distribution prefer stock purchase right dividend share common stock purchase right currently exercisable certain condition involve acquisition propose acquisition person group common stock purchase right permit holder holder purchase common stock discount market price time payment specify exercise price purchase right addition event certain business combination purchase right permit purchase common stock acquirer discount market price time certain condition purchase right redeem table content gilead sciences inc note consolidated financial statementscontinue board price purchase right purchase right voting privilege attach automatically trade common stock october october board approve amendment right plan amendment provide thing increase exercise price right plan extension term plan november october second amendment provide thing increase exercise price right plan extension term right plan october amendment clarify amendment enter connection increase designate number share series junior participate prefer stock potential issuance right plan stock option plan stockholder approve adopt equity incentive plan plan stock option nexstar pharmaceuticals inc nexstar triangle pharmaceuticals inc triangle corus myogen stock option plan assume result acquisition nexstar triangle corus myogen convert option purchase common stock effective closing respective acquisition plan broad base incentive plan allow award grant employee director consultant plan provide option grant designate nonqualifie incentive stock option prior january grant nonqualified incentive stock option stock option grant january nonqualified stock option plan employee stock option generally vest year exercisable period exceed contractual term year date stock option issue grant price fair value common stock grant date stock option exercise settle newly issue common stock plan previously authorize available pool share stockholder approve increase additional share common stock available issuance plan december total share common stock authorize grant share remain available future grant plan follow table summarize activity stock option plan option grant present table exercise price fair value underlie common stock grant date share thousand year end december weight weight weight average average average share exercise price share exercise price share exercise price outstanding beginning year grant assume forfeit exercise outstanding end year exercisable end year weightedaverage grant date fair value option grant year table content gilead sciences inc note consolidated financial statementscontinue total intrinsic value option exercise year end december million million million respectively total fair value stock option vest year end december million million million respectively december number option outstanding expect vest net estimate future option forfeiture accordance provision sfas r weightedaverage exercise price aggregate intrinsic value million weightedaverage remain contractual life year aggregate intrinsic value stock option outstanding stock option exercisable december billion billion respectively december weightedaverage remain contractual life option outstanding stock option exercisable year respectively follow summary stock option outstanding stock option exercisable december option thousand option outstanding option exercisable weighted weighted option average option average range exercise price outstanding exercise price exercisable exercise price total december million unrecognized compensation cost relate stock option expect recognize estimate weightedaverage period year performance share restrict stock award january grant performance base share award plan award divide tranche vest performance measurement purpose subject achievement specify market performance goal relative predetermine peer group awards vest year period actual number share common stock ultimately issue calculate multiplying number performance share payout percentage range performance share vest committee subcommittee board determine achieve specified market performance goal fair value performance share estimate grant date monte carlo valuation methodology stockbase compensation performance share recognize expense requisite service period straight line expense attribution approach reduce estimate forfeiture weightedaverage grant date fair value performance share share recognize million million stockbase compensation expense respectively relate performance share january grant performance base share award term substantially similar award grant single year performance measurement vest period table content gilead sciences inc note consolidated financial statementscontinue weightedaverage grant date fair value performance share share recognize million stockbase compensation expense relate performance share grant restrict stock award certain employee plan vest certain award subject achievement specify performance goal number restrict stock award issue date significant december nonveste outstanding award respectively employee stock purchase plan employee stock purchase plan amend espp employee purchase share common stock base percentage compensation subject certain limit purchase price share equal low fair value common stock offering date purchase date year lookback feature espp cause offer period reset fair value common stock purchase date original offering date espp purchase employee settle newly issue common stock espps previously authorize available pool share stockholder approve amendment espp increase number share authorize reserved issuance espp additional share common stock extend term espp additional year january share issue espp million total share common stock reserve issuance espp share available issuance espp december december million unrecognized compensation cost relate espp expect recognize estimate weightedaverage period year stockbase compensation january adopt provision sfas r require sharebase payment employee director include grant stock option recognize consolidated statement operation base fair value table summarize stockbase compensation expense sfas r thousand share amount year end december cost good sell research development expense sell general administrative expense stockbase compensation expense include total cost expense income tax effect stockbase compensation expense include net income loss stockbase compensation expense include net income loss share basic diluted table content gilead sciences inc note consolidated financial statementscontinue year end december capitalize million million million stockbase compensation cost inventory respectively stockbase compensation recognize expense requisite service period consolidated statement operation grade vest expense attribution approach nonveste stock option grant prior adoption sfas r straightline expense attribution approach stock option grant adoption sfas r stockbase compensation expense relate stock option recognize adoption sfas r base award ultimately expect vest gross expense reduce estimate forfeiture sfas r require forfeiture estimate time grant revise necessary subsequent period actual forfeiture differ estimate estimate forfeiture base historical experience prior adoption sfas r pro forma information require sfas include forfeiture occur result adoption sfas r recognize tax benefit stockbase compensation apic incremental tax benefit realize tax attribute currently available utilize addition elect account indirect benefit stockbase compensation research tax credit extraterritorial income deduction consolidate statement operation apic valuation assumption fair value award grant stock option plan espp estimate grant purchase date blackschole option valuation model blackschole option valuation model develop use estimate fair value trade option vest restriction fully transferable addition option valuation model require input highly subjective assumption include expect stock price volatility expect award life connection adoption sfas r refine methodology derive valuation model assumption follow assumption calculate estimate fair value award year end december expect volatility stock option espp expect term year stock option espp riskfree interest rate stock option espp expect dividend yield fair value stock option grant prior adoption sfas r calculate multiple option approach fair value stock option grant begin january calculate single option approach prior adoption sfas r historical stock price volatility connection blackschole option valuation model connection adoption sfas r determined blend historical volatility imply volatility trade option common stock well reflection expect volatility table content gilead sciences inc note consolidated financial statementscontinue expect term stockbase award represent weightedaverage period award expect remain outstanding estimate weight average expect term base historical cancellation historical exercise datum relate stock option contractual term vest term award riskfree interest rate base observe interest rate appropriate term stockbase award dividend yield base history expectation dividend payout comprehensive income loss comprehensive income loss comprise net income loss certain change stockholder equity exclude net income loss change fair value outstanding effective cash flow hedge change unrealize gain loss availableforsale security change cumulative foreign currency translation account comprehensive income loss year end december include consolidated statement stockholder equity component comprehensive income loss show net relate taxis underlie asset liability hold jurisdiction expect generate future tax benefit liability follow reclassification record connection net realize gain loss sale security cash flow hedge previously include comprehensive income loss thousands year end december net unrealized gain loss relate availableforsale security net tax benefit provision respectively net unrealized gain loss relate cash flow hedge net tax benefit provision respectively reclassification adjustment net tax benefit respectively comprehensive income loss balance accumulate comprehensive income loss net taxis report consolidated balance sheet consist follow component thousand december net unrealized gain loss availableforsale security net unrealize gain loss cash flow hedge cumulative foreign currency translation adjustment accumulate comprehensive income loss disclosure segment enterprise related information operate business segment primarily focus development commercialization human therapeutic life threaten disease product include segment major table content gilead sciences inc note consolidated financial statementscontinue product truvada atripla viread hepsera emtriva ambisome account substantially total product sale year end december similar economic characteristic include nature product production process type customer distribution method regulatory environment product sale consist follow thousands year end december antiviral product truvada atripla viread hepsera emtriva total antiviral product ambisome letairis total product sale follow table summarize total revenue external customer collaboration partner geographic region thousand product sale product relate contract revenue attribute country base shipto location royalty nonproduct relate contract revenue attribute country base location collaboration partner year end december united states outside united states france spain united kingdom italy germany switzerland european country country total revenue outside united states total revenue december net book value property plant equipment united states ireland canada million million million respectively comprise approximately total net book value property plant equipment table content gilead sciences inc note consolidated financial statementscontinue follow table summarize revenue customer individually account total revenue total revenue year end december cardinal health inc mckesson corp amerisourcebergen corp f hoffmannla roche ltd income taxis provision income taxis consist follow thousands year end december federal current deferred state current defer foreign current defer provision income taxis foreign pretax income million million million respectively cumulative unremitted foreign earning consider permanently invest outside united states taxis provide approximately billion billion december respectively residual tax liability amount remit approximately million million december respectively table content gilead sciences inc note consolidated financial statementscontinue difference provision income taxis compute apply federal statutory income tax rate income loss provision income taxis follow thousands year end december income loss provision income taxis tax federal statutory rate state taxis net federal benefit foreign earning different rate purchase inprocess rd expense research credit net unbenefite stock compensation provision income taxis defer income taxis reflect net tax effect temporary difference carry amount asset liability financial reporting purpose amount income tax purpose significant component defer tax asset liability follow thousand december defer tax asset convertible note hedge stockbase compensation capitalize intangible reserve accrual currently deductible depreciation relate research tax credit carryforward net operating loss carryforward net total defer tax asset valuation allowance valuation allowance total defer tax asset defer tax liability unremitte foreign earning total defer tax liability net defer tax asset valuation allowance increase decrease million million million year end december respectively conclude base standard set forth sfas likely realize benefit defer tax asset relate certain state net operating loss tax credit carryforward december release related valuation allowance result credit goodwill approximately million income tax benefit approximately million table content gilead sciences inc note consolidated financial statementscontinue december federal net operating loss carryforward approximately million federal net operating loss carryforward start expire utilize federal tax credit carryforward approximately million start expire utilize addition state net operating loss tax credit carryforward approximately million million respectively state net operating loss tax credit carryforward start expire respectively utilize utilization net operating loss tax credit subject annual limitation ownership change limitation provide internal revenue code amend similar state provision annual limitation result expiration net operating loss credit utilization file federal state foreign income tax return jurisdiction unite states abroad federal california income tax purpose statute limitation remain open year inception utilization net operating loss relate prior year income tax return audit federal state foreign tax authority currently examination internal revenue service irs tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction periodically evaluate exposure associate tax filing position december total federal state foreign unrecognized tax benefit million million respectively include interest million million respectively total unrecognized tax benefit december million million respectively recognize reduce effective tax rate period recognition permit provision fin continue classify interest penalty relate unrecognized tax benefit income tax provision consolidate statement operation reach agreement irs issue relate examination federal income tax return result reduce unrecognized tax benefit million december believe reasonably possible unrecognized tax benefit decrease approximately million month expect clarification irs certain uncertain tax position respect remain unrecognized tax benefit currently unable reasonable estimate period cash settlement respective tax authority table content gilead sciences inc note consolidated financial statementscontinue follow rollforward total gross unrecognized tax benefit liability year end december thousand december balance beginning period tax position relate current year addition reduction tax position relate prior year addition reduction settlement lapse statute limitation balance end period defer compensation plan maintain retirement saving plan eligible employee defer compensation income tax purpose section k internal revenue code gilead plan gilead plan employee contribute eligible annual compensation subject irs plan limit match contribution gilead plan contribute employee contribution annual maximum match contribute employee contribution annual maximum match respectively total matching contribution expense gilead plan million million million maintain deferred compensation plan director key employee defer compensation income tax purpose defer compensation plan nonqualifie defer compensation plan subject qualification requirement section internal revenue code compensation defer december subject requirement section internal revenue code plan officer senior grade level employee contribute annual salary annual bonus director contribute annual retainer fee amount defer participant deposit rabbi trust record noncurrent asset consolidate balance sheet begin director elect receive portion annual cash retainer phantom share give participant right receive equal value specify number share specify period time payable share common stock fractional share pay cash establish plan administrator december phantom share outstanding participant elect distribution date available plan receive defer compensation payment table content gilead sciences inc note consolidated financial statementscontinue quarterly result operation unaudite follow amount thousand share amount st quarter nd quarter rd quarter th quarter total revenue gross profit product sale total cost expense net income net income sharebasic net income sharedilute total revenue gross profit product sale total cost expense net income net income sharebasic net income sharedilute second quarter recognize million charge purchase iprd associate acquisition asset navita relate cicletanine business table content gilead sciences inc schedule ii valuation qualifying account balance addition balance begin charge end period expense deduction period year end december account receivable allowance valuation allowance defer tax asset year end december account receivable allowance valuation allowance defer tax asset year end december account receivable allowance valuation allowance defer tax asset allowance doubtful account sale return cash discount chargeback valuation allowance defer tax asset include million million december respectively relate acquisition table content